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ULTRASOUND BASED HIGH DOSE RATE PROSTATE
BRACHYTHERAPY TREATMENTS
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High dose rate (HDR) brachytherapy is a treatment modality commonly used for
the treatment of prostate cancer. In this technique, radiation is emitted from within
the prostate, allowing for high doses to be delivered to the prostate whilst still sparing
the surrounding organs at risk such as the urethra, bladder, and rectum. However,
due to the close proximity of these organs at risk to the prostate, and therefore the
radiation source, there is potential that small errors in placement of the source may lead
to substantial changes in the delivered dose distribution. Consequently, these errors
may lead to significant post-treatment gastrointestinal or genitourinary complications
as well as suboptimal biochemical progression free survival.
Due to the risk of HDR prostate brachytherapy (pBT) mistreatment resulting
in significant post-treatment complications, it is essential that all potential risks in
the treatment planning and delivery process are identified, and that these risks are
minimised. One method of minimising these risks is through the implementation of
routine in-vivo treatment verification (IVTV), through either in-vivo dosimetry or
in-vivo source tracking.
The aim of this thesis is to identify all types of potential treatment planning and
delivery errors for transrectal ultrasound (TRUS) based HDR pBT and to investigate
the feasibility of reducing the impact of these errors through the introduction of routine
IVTV. To achieve this, a novel two-dimensional diode array known as the Magic Plate
will be considered for in-vivo source tracking, and novel MOSFET type dosimeter
known as the MOSkin will be considered for in-vivo dosimetry of TRUS based HDR
pBT.
KEYWORDS: prostate, brachytherapy, in-vivo source tracking, in-vivo dosimetry,
Magic Plate, MOSkin
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In Australia, over 75 000 people with cancer will need radiation therapy in 2020 [6].
Despite improved screening, prostate cancer still remains one of the leading causes of
death for Australian males, accounting for 3824 deaths in 2011. The projected number
of deaths from prostate cancer is expected to increase to more than 3900 per year by
2020 [6]. It is also predicted that the incidence of prostate cancer will rise to 25 000
from 21 000 new cases per year during the same span [6]. Similar trends have been
observed on a world scale, with 250 000 deaths per year due to prostate cancer, the
burden of which is expected to rise to 499 000 new deaths [7].
High dose rate (HDR) brachytherapy is a form of radiation therapy that is com-
monly used for the treatment of prostate cancer. In this form of therapy, the ra-
dioactive source (typically Ir-192) is temporarily placed at multiple positions within
the prostate for a prescribed amount of time. To achieve this, thin catheters are
temporarily inserted into the trans-perineally under trans-rectal ultrasound (TRUS)
guidance. The HDR source is then stepped through these catheters sequentially, driven
by a device called a remote afterloader.
As in HDR pBT the radiation source is placed directly within the target in HDR
prostate brachytherapy (pBT), ablative doses can be delivered to the prostate whilst
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still sparing adjacent organs at risk (OARs), such as the urethra, rectum, and the
bladder [8]. This is also made achievable due to the millimetre precision of the equip-
ment and the steep dose gradients associated with Ir-192 source. These steep dose
gradients however also necessitate strict quality assurance (QA), as small differences
between planned and measured source positions within the target may result in a
severe underdosage of the target and/or overdosage of OARs [9].
HDR pBT treatments are traditionally planned on computed tomography (CT)
scans of the patient after implantation of the catheters. However, the use of TRUS
for treatment planning has been increasing rapidly in recent years due to its excellent
visibility of the prostate and surrounding OARs [10]. Modern TPSs are able to use the
ultrasound (US) echoes of the implanted catheters for the definition of the catheter
position within the patient, allowing for real-time HDR pBT treatment planning [11].
HDR pBT is both intensive and complex, and therefore robust methods of QA are
required.
Traditional methods of QA for HDR pBT focus on minimising the risk of after-
loader malfunction [9]. It is now beginning to be recognised however that the likelihood
of afterloader malfunction is low, and that there are many other steps in the treat-
ment planning and delivery process that may result in incorrect delivery of treatment
[12]. This is true especially the complex process of TRUS based HDR pBT treatment
delivery.
Consequently, an ultimate QA program for TRUS based HDR pBT should consider
all potential errors in the treatment planning and delivery process. The potential inci-
dence and severity of these errors may be reduced, and detectability increased through
introduction of department specific procedures, protocols, and checklists. However,
these checklists and procedures are not likely to catch errors, and they should be sup-
plemented through some form of in-vivo treatment verification (IVTV) such as in-vivo
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dosimetry (IVD) or in-vivo source tracking.
1.1 Project Aim
The aim of this project is to identify all types of potential treatment planning and
delivery errors for TRUS based HDR pBT and reduce the impact of these errors
through the introduction of IVTV. This aim is divided into the following objectives:
 Review the literature for current methods of IVTV in HDR pBT.
 Identify all potential risks associated with the TRUS based HDR pBT process.
 Assess the applicability of IVTV to detect and reduce the risk associated with
these errors.
 Determine appropriate action thresholds for in-vivo source tracking in TRUS
based HDR pBT.
 Evaluate the feasibility of using an two-dimensional (2D) diode array to perform
in-vivo source tracking in HDR pBT.
 Benchmark a novel dosimeter against more established dosimeters in performing
IVD during TRUS based HDR pBT.
 Perform a clinical trial in which the novel dosimeter is used for IVD during TRUS




The prostate gland is part of the male reproductive system and is approximately the
size and shape of a walnut. The gland is located immediately anterior to the rectum
and inferior of the bladder, completely surrounding the urethra. The urethra is central
to the prostate at its inferior aspect (apex) but located more anteriorly at the superior
aspect (base). Its main function is to secrete fluids that protect and enrich sperm.
According to the McNeal model, the prostate gland can be divided into zones [13].
The urethra runs through the centre of the prostate, with the fibromuscular stroma
immediately anterior to the urethra and the glandular tissue immediately posterior.
The glandular tissue can then be divided into three zones; the peripheral zone (PZ), the
central zone (CZ) and the transition zone (TZ). The PZ comprises of approximately
70% of the glandular tissue, located primarily at the apex of the prostate. The CZ
comprises 25% of the glandular tissue, and the TZ up to 10% and is separated into 2
equal sized portions lateral to the urethra and anterior to the peripheral zone in the
mid-prostate [13].
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2.1.1 Prostate Cancer
Prostate cancer is a disease that occurs when cells in the prostate gland become abnor-
mal and grow uncontrollably to form tumours. Whilst cancerous cells in the prostate
are generally not responsible for deaths on their own, they are capable of metasta-
sising (spreading to other parts of the body) via the blood or lymphatic system and
producing new tumours. Approximately 60% of prostate cancers are found in the PZ,
8% in the CZ and 24% in the TZ [13]. Prostate cancer exhibits few symptoms while
the disease is confined within the gland [14]. Traditionally, patients were examined for
prostate cancer using a digital rectal exam. The development of new techniques such as
the measurement of prostate-specific antigen (PSA) levels and the use of TRUS guided
biopsies has improved the screening for prostate cancer and decreased the mortality
rate [15].
2.2 Treatment of Prostate Cancer
In non-metastatic prostate cancer patients, the most frequently used treatment modal-
ities are radical prostatectomy (removal of the prostate), radiotherapy and active
surveillance. Overall, approximately 50% of mean with localized prostate cancer
undergo radical prostatectomy and 25% receive radiotherapy (external beam radio-
therapy and/or brachytherapy) [16]. The decision-making process regarding primary
treatment often depends on many factors, including TNM classification and PSA. The
potential side effects profile of surgery and radiotherapy vary enormously; prostate-
ctomy has been shown to cause more urinary incontinence and erectile dysfunction
[17, 18] whereas radiotherapy causes more urinary irritation and bowel/rectal symp-
toms [17, 19]. The severity of treatment side effects are also often key factors in the
treatment decision.
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2.2.1 High Dose Rate Brachytherapy
Brachytherapy is radiation therapy treatment modality where a radiation source is
placed close to, or within the tumour to be treated. Radiation is emitted from the
source randomly in all directions, the intensity of which decreases following the inverse
square law. Adherence to the inverse square law results in steep dose gradients around
the source, allowing for large doses to be delivered to the tumour whilst still sparing
surrounding OARs
Brachytherapy can be separated into two categories; removable, and permanent
source implants. HDR brachytherapy, which is the type of brachytherapy that will
be investigated in this thesis, makes use of removable implants. Characteristics of
HDR brachytherapy sources include; high specific activity (341 TBq/g), high dose
rate (>12 Gy/hour), medium energy (average energy of gamma emission being 0.38
MeV) photons delivered for a short period of time (5-20 minutes). HDR sources were
traditionally implanted manually, but recent advances in technology have allowed for
remote afterloading techniques, resulting in a reduction of radiation exposure to staff.
Catheters are surgically inserted directly into the tumour, usually under the guidance
of US or C-arm CT. Once all the catheters have been inserted, the patient is taken
for imaging from which a treatment plan is created and delivered remotely by the
afterloading machine. The most commonly used HDR brachytherapy source is Ir-192.
2.3 Clinical Indications for HDR Prostate Brachyther-
apy
The current standard of care for intermediate and high risk prostate cancer patients
involves the use of a combination of external beam radiotherapy (EBRT) and HDR
brachytherapy [20]. This typically involves a prescription of approximately 46 Gy
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(in 2 Gy per fraction) to the prostate and/or lymph nodes using EBRT and a con-
formal boost of 15 Gy (in 1 fraction) fraction using HDR brachytherapy. However,
recent technological advances in EBRT such as intensity modulated radiation therapy
(IMRT), volumetric modulated radiotherapy (VMAT) and image guided radiotherapy
(IGRT) as well as the use of hypofractionated schedules [21] have resulted in improve-
ments in dose conformity of EBRT, allowing larger biological doses to be prescribed
whilst still decreasing normal tissue toxicities [22]. These advancements have caused
some to question the need for HDR brachytherapy in this setting and it is currently a
major subject of debate in the literature [23]. However, there have been a number of
recent studies however showing improved quality of life outcome for combined EBRT
and HDR brachytherapy compared with EBRT alone [24, 8, 25] and several studies
have reported favourable results using HDR brachytherapy alone [26, 27].
2.4 The Ir-192 Source
One of the most commonly used sources in HDR brachytherapy is Ir-192 (Figure 2.1),
due to a number of characteristics which make it attractive for its use with the remote
afterloading technique. The source has a high specific activity (341 TBq/g), allowing
for relatively large amounts of activity to be contained within a small source (approx-
imately 5 mm length and 1 mm diameter) that can be inserted into the catheters used
in remote afterloading. Radiation therapy departments typically receive a source of
approximately 40 µGym2/hr and the half-life of the source is 73.83 days, therefore the
source can be used for up to 3 months allowing for treatments of approximately 10-20
minutes.
Ir-192 is produced by neutron bombardment of the stable Ir-191 isotope and decays
by β emission to Pt-192 95.1% of the time and through electron capture to Os-192
4.9% of the time. There are approximately 2.21 photons emitted per decay of the
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Figure 2.1: Image of the Ir-192 Flexisource with ruler for scale.
source in the energy range from 9.44 1378.5 keV with a weighted mean energy of 354
keV (for the stainless steel encapsulated source used clinically). The complex spectrum
of photon energies emitted from the source is summarised in Table 2.1, obtained from
the NuDat database [1].
2.5 The TG-43 Dosimetry Protocol
In 1995 the American Association of Physicists in Medicine (AAPM) Task Group
43 released a report entitled Dosimetry of Interstitial Brachytherapy Sources [9]. In
this report the task group provided a dose calculation formalism for Ir-192, I-125 and
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Pd-103 brachytherapy sources [3]. This report was updated in 2004 (TG43-U1) to;
include new brachytherapy sources released since the publication of the first report,
critically reassess published brachytherapy dosimetry data, and to eliminate minor
inconsistencies from the original report. The following paragraphs summarise the
TG43-U1 calculation formalism. The general 2D dose rate formalism can be expressed
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using the following equation:
Ḋr(r, θ) = SK∆
GL(r, θ)
GL(r0, θ0)
gL(r)F (r, θ) (2.1)
Where r denotes the distance (in centimetres) from the centre of the active source
to the point of interest, r0 denotes the reference distance which is specified to be 1 cm
in this protocol, and θ denotes the polar angle specifying the point of interest P(r,θ),
relative to the source longitudinal axis. The reference angle θ = 0 defines the source
transverse plane, and is specified to be 90 or π/2 radians.
Figure 2.2: TG43-U1 coordinate system used or brachytherapy dosimetry calculations
[3].
SK is the air kerma strength, which has units of µGym
2/h (U) and is numerically
identical to the quantity Reference Air Kerma Rate recommended by ICRU 38 [28]
and ICRU 60 [29]. Air kerma strength is the air kerma rate (Kδ(d)) in vacuo and due
to photons of energy greater than δ, at a distance d, multiplied by the square of this




The quantity d is the distance from the source centre to the point of air kerma rate
specification which should be located on the transverse plane of the source. The energy
cutoff δ, is intended to exclude low-energy or contaminant photons (e.g. characteristic
x-rays originating in the outer layers of steel or titanium source cladding) that increase
the air kerma rate without contributing significantly to dose at distances greater than
0.1 cm in tissue. This value δ is typically 5 keV for low-energy photon emitting
brachytherapy sources.
The dose-rate constant in water, ∆, is the ratio of dose rate at the reference position
P(r0,θ0) and SK . ∆ has units of cGy/Uh. The dose-rate constant depends on both the
radionuclide and source model, and is influenced by both the source internal design
and the experimental methodology used by the primary standard to realise SK .
The purpose of the geometry function is to improve the accuracy with which dose
rates can be estimated by interpolation from data tabulated at discrete points. Phys-
ically, the geometry function neglects scattering and attenuation, and provides an ef-
fective inverse square law correction based upon an approximate model of the spatial
distribution of radioactivity from within the source. The TG43-U1 protocol recom-
mends the use of point or line source models giving rise to the following geometry
functions:
Gp(r, θ) = r











line source approximation if θ=0 (2.5)
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Where B is the angle, in radians, subtended by the tips of the hypothetical line
source with respect to the calculation point, P(r,θ). The protocol recommends consis-
tent use of the line-source geometry function for evaluation of 2D dose distributions
[3].
The radial dose function, g(r), accounts for dose fall-off on the transverse plane
due to photon scattering and attenuation i.e., excluding dose fall-off included by the
geometry function and is equal to unity at r0 = 1 cm.
The 2D anisotropy function describes the variation in dose as a function of polar
angle relative to the transverse plane. The value of F(r,θ) off the transverse plane
typically decreases as r decreases, as θ approaches 180, as encapsulation thickness
increases, and as photon energy decreases. The active length, L, used to evaluate
the geometry function, should be the same used to extract the radial dose and 2D
anisotropy functions. Otherwise, significant errors in dosimetry at small distances
may arise.
The uncertainty in the dose rate at any given depth is calculated by computing
the sum of squares of the associated uncertainties of all the factors outlined above.
One also must take into account the uncertainty associated with the specified source
strength (the uncertainty in the source strength given on the calibration certificate
of Ir-192 sources as 5%, however according to AAPM Task Group Report 138 [30]
the source strength measurement in the clinic using an appropriately calibrated well
chamber yields an uncertaity of 2k6%). Thus combining all of the uncertainties yields
a total uncertainty in the dose rate of 8.5-11.7% at 1 cm and 9.2-12.2% at 0.1 cm.
However, the uncertainty at 0.1 cm may be even higher in brachytherapy treatment
planning systems (BTPS), due to insufficient published F(r,θ) data for small angles of
θ [3].
The TG43-U1 protocol is currently the standard for BTPS dose calculation, sup-
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plemented by the recommendations from the AAPM and European Society for Ra-
diotherapy and Oncology (ESTRO) on dose calculations for high energy (> 50 keV)
photon emitting brachytherapy sources published in 2012 [31]. However, this type
of dose calculation model is only strictly valid for calculations in homogeneous wa-
ter phantoms, of the same size and shape used to obtain the model parameters [3].
This presents a severe limitation of the algorithm in regions of heterogeneous densities
(metal applicators, prostate calcifications) [32], near air interfaces (breast, rectum,
small bowel) [33] and for low energy brachytherapy sources (I-125) [34]. This has
led to the development of model based dose-calculation algorithms (MBDCAs) where
radiation transport is modelled in non-water mediums, resulting in more accurate de-
termination of dose delivered to the patient in BTPS. A description of the guidelines
for MBDCAs was developed by the AAPM Task Group 186 [35].
2.6 High Dose Rate Prostate Brachytherapy Plan-
ning and Treatment Process
The traditional CT based HDR brachytherapy process begins with the patient being
placed under anaesthetic and their legs moved to the lithotomy position. TRUS is
then used to determine the shape and size of the prostate and guide the insertion
of catheters into the prostate [36]. The catheters enter the body via the perineum,
over which a template is placed that aids in the identification of the catheters during
planning and treatment. Once the required number of catheters have been inserted
the patient is transferred to a CT scanner for imaging, during which a helical scan is
obtained with 1 mm slice spacing [36].
The CT scan is then used for treatment planning, beginning with the contouring
of the prostate, rectum, urethra and bladder by the radiation oncologist (RO) on the
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BTPS. Digital reconstruction of the catheters is then performed by the brachytherapy
team, followed by the selection of the type of optimisation to be used in creating the
treatment plan. Plan optimisation can be performed via a number of methods, the
most common of which usually involves a method of inverse planning. Inverse Planning
is the process through which the TPS determines the dwell positions and times of the
HDR source within the catheters in order to best shape the dose distribution around
the PTV and minimize the dose to the OARs [37].
Once the plan has been approved by the RO the plan is transferred to the treat-
ment console system (TCS) and some treatment plan checks are performed by the
brachytherapy team. The patient is then transferred to the brachytherapy treatment
bunker and catheters connected to the HDR remote brachytherapy afterloader. The
afterloader receives treatment plan data from the TCS and controls the placement of
the Ir-192 source through each catheter [38]. The Ir-192 source is welded to a steel
cable that is wound around a drum inside of the afterloader device, positioning of
the source is achieved through rotation of the drum using stepper motors varying the
source position through the desired catheter for a time specified by the TCS [38].
One example of a HDR brachytherapy remote afterloader is the Flexitron HDR af-
terloader produced by Elekta (Elekta Brachytherapy, Veendendaal, The Netherlands).
The afterloader is able to support up to 40 catheters and a minimum step size of 1
mm. The Ir-192 source positioning accuracy has been shown to be better than ± 0.5
mm and a dwell time resolution 0.1 seconds has been proven [39]. The Flexitron HDR
afterloader will be investigated in this thesis.
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2.6.1 Transrectal Ultrasound Based High Dose Rate Prostate
Brachytherapy Planning
The use of TRUS for treatment planning has been increasing rapidly in recent years due
to its excellent visibility of the prostate and surrounding OARs [10]. Modern TPSs are
able to use the US echoes of the implanted catheters for the definition of the catheter
position within the patient, allowing for real-time HDR pBT treatment planning [11].
This technique results in a dramatic decrease in the time required for the HDR pBT
planning and treatment process, from 4-6 hours down to approximately 2 hours [40].
The major advantage of this is the removal of the requirement to correct for catheter
displacements relative to the prostate in the time between imaging and treatment,
which has been shown to be strongly correlated with time [41]. The definition of the
catheter position however strongly affects the dose distribution in brachytherapy, and
as this is a new technique there is a need for more comprehensive pre-treatment or
in-vivo QA [10]. A more detailed description of the real-time TRUS based HDR pBT
workflow will be given in future chapters of this thesis.
2.7 High Dose Rate Brachytherapy Mistreatments
and the Requirement for Quality Assurance
There are a number of published documents by the International Commission on Radi-
ological Protection (ICRP) [42, 43] as well as the International Atomic Energy Associa-
tion (IAEA) [44] that describe errors that have occurred in HDR brachytherapy. Many
of these errors are related to human miscalculations, less often they are due to ma-
chine or computational malfunction. Some examples of human errors include incorrect
source strength entered into the planning system, patient misidentification, incorrect
site of treatment, incorrect prescription, incorrect catheter connection or incorrect
2.7. High Dose Rate Brachytherapy Mistreatments and the Requirement for Quality
Assurance 21
applicator placement. Other errors that may occur include; mistakes or uncertain-
ties in identification of applicator length on 3D imaging, incorrect import/export of
treatment plan from planning system and organ/applicator movement between imag-
ing and treatment [44]. The likelihood of remote afterloader malfunction is generally
considered as extremely low, however small deviations from the plan in source dwell
position and time can result in significant errors in the dose delivered to the patient
[45].
A successful HDR brachytherapy treatment is one where the source is driven to the
planned position, in the planned catheter, for the desired amount of time. Successful
execution of these three parameters will ensure that the delivered dose distribution
matches the one calculated by the brachytherapy TPS. With the introduction of inverse
planning optimisation techniques, the complexity of HDR brachytherapy treatment
planning has increased significantly. Therefore, it is essential that QA techniques
continue to evolve at the same rate. The AAPM Radiation Therapy Task Group
No.59 recommends that institutions employ a QA program that exploits redundancy,
and review the entire treatment planning and delivery process to isolate any actions
susceptible to errors. The report suggests that incidence of these errors may be reduced
by the introduction of pre-treatment QA in the time between treatment planning and
delivery [38]. Further to this, another AAPM Report from the Radiation Therapy
Task Group 56 recommends that the source position, source dwell time and transit
time be quantified by the medical physicist on a regular basis [36]. A combination of
these regular and pre-treatment QA checks, along with a well-documented treatment
planning and delivery protocol will go a long way to ensuring safe and successful
delivery of HDR brachytherapy treatment plans.
However, this type of QA program will not safeguard the HDR brachytherapy de-
livery from all types of errors. More recently, the AAPM published the Task Group
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100 report, which describes a risk based approach to the development of quality man-
agement (QM) [2]. It has been shown in some publications that this type of approach
to QM may result in an improved QA program when compared to more traditional
methods of QM [46].
Therefore, an ideal QM program for HDR pBT should be one that considers all po-
tential errors in the treatment planning and delivery process, and may be supplemented
by a system that provides real-time identification of the dwell positions, measure the
dwell and transit times, and compare these parameters with the prescribed treatment
plan both before and during treatment [47].
2.8 Current Methods of High Dose Rate Brachyther-
apy In-vivo Dosimetry
One method of performing IVTV for HDR brachytherapy is through the use of IVD.
IVD for HDR brachytherapy has been referenced in international recommendations
as far back as 1985 by the International Commission on Radiation Units and Mea-
surements (ICRU)[48]. Since this time, the complexity of brachytherapy has increased
exponentially due to the introduction of remote afterloading devices, three-dimensional
(3D) imaging and inverse planning. However, despite this increase in complexity, sys-
tematic patient specific QA of dose delivery is still not performed. Additionally, the
large dose per fraction (>5 Gy) delivered during brachytherapy treatments means that
the consequence of an error in the dose delivery process may be substantial compared
to EBRT [44]. Therefore, IVD in HDR brachytherapy should be considered an essen-
tial part of the treatment QA process. Unfortunately, performing accurate and precise
IVD in brachytherapy is extremely difficult due to the challenges of precise detector
positioning and the high dose gradient fields.
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There are a number of published documents by the ICRP [43, 42] as well as the
IAEA [44] that describe errors that have occurred in HDR brachytherapy. A number
of these errors can be identified by a rigorous brachytherapy QA schedule and manual
safety checks prior to treatment. However, not all of these errors can be covered by
such checks. In these cases, routine IVD can be a useful tool to complement QA and
manual checks prior to treatment for HDR brachytherapy.
2.8.1 Challenges associated with HDR Brachytherapy In-vivo
Dosimetry
Brachytherapy dose distributions, especially at close distances to the source, are char-
acterized by steep gradients (e.g. 50%/mm at 4 mm distance and 6%/mm at 20 mm
distance). Because of this, accurate detector positioning is crucial in IVD and small
uncertainties in positioning can lead to unacceptably large deviations in measured dose
[49].
Another major challenge for IVD in HDR brachytherapy is the energy dependence
of the detectors used in energy range of Ir-192. The energy dependence of the detector
is defined as the dependence of the detector reading as a function of the absorbed
dose in water on the photon or electron energy spectrum. This has implications both
for calibration of the dosimeter and for conversion of detector reading into measured
dose during patient measurements, as the energy spectrum measured by the dosimeter
changes significantly with distance from the source [49].
2.8.2 Thermoluminscent Dosimeters
Thermoluminescent dosimeters (TLDs) have historically been used for IVD in HDR
brachytherapy [50]. Lithium Fluoride (LiF) TLD rods have been the most widely
used due to their ability to fit into catheters. However, TLDs require special handling
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procedures, individual calibration and a long annealing process which does not allow
them to give an instantaneous read-out. When considering these limitations, is can
be established that there are other dosimeters that are more suitable for IVD in HDR
brachytherapy.
2.8.3 Semiconductor Diodes
Conversely, semiconductor diodes to have the advantage of providing the user with
an instantaneous read-out. They also have the desirable dosimetric characteristics of
high sensitivity (approximately 18,000 times higher than an ionisation chamber of the
same volume), mechanical stability and small physical dimensions (typically of the
order of 1 mm). However, they also have the undesirable dosimetric characteristics of
energy and directional dependence, temperature dependence and changes in radiation
sensitivity due to radiation damage. Although, these undesirable characteristics can be
measured and accounted for using phantom measurements prior to clinical application.
Two studies exist in which a diode array manufactured by PTW was used for IVD
for patients undergoing HDR brachytherapy treatments [51, 52]. Seymour et al. [51]
performed IVD inside the rectum for prostate HDR brachytherapy patients. When
comparing against the TPS, measured values ranged from -42% to +35%. Waldhausl
et al. [52] used the same rectal probe and a bladder probe consisting of a single
diode for IVD of cervix HDR brachytherapy treatments. Their measured values, when
compared against the BTPS ranged from -31% to +90% for the rectum and -27% to
+26% for the bladder. These results re-enforce the notion that performing accurate
and precise IVD in brachytherapy is extremely difficult due to the challenges of precise
detector positioning and the high dose gradient fields.
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2.8.4 MOSFETs
MOSFET detectors have similar advantages and disadvantages to diodes in their ap-
plication to IVD of HDR brachytherapy. Although unlike diodes, their temperature
dependence can be overcome by using specially designed dual-MOSFT-dual bias de-
tectors [53]. They can also be produced in smaller size compared to diodes (typically
by an order of magnitude), allowing them to be placed inside intraluminal catheters
and even needles. One example of their application in HDR brachytherapy is their
characterization of Leipzig surface dose applicators, which were found to agree with
Monte Carlo simulations to within 3% [54].
Mason et al. performed IVD for HDR pBT by placing a single MOSFET into an
additional needle [55]. An expanded measurement uncertainty was calculated to be
31.9% and 12.3% per needle and per plan, respectively (k=2). The largest contributor
to measurement uncertainty was attributed to the positional uncertainty of the MOS-
FET relative to the source (13.0% and 4.1% per needle and per plan, respectively).
An error detector threshold of this magnitude is unacceptably large and could result
in errors going undetected by the system.
Carrara et al. have demonstrated an improved measurement uncertainty using
MOSFET dosimeters (namely MOSkin dosimeters), through coupling of the dosime-
ters to the TRUS probe during HDR pBT [56, 57]. By coupling the MOSkin dosimeters
to the TRUS probe, the uncertainty of relating the position of the dosimeters relative
to the source was reduced significantly. Consequently, in-vivo measurements over 18
treatment fractions yielded an agreement with treatment planning predicted doses to
within 3.6% ± 1.9% [57]. It is this type of approach that will be reproduced in this
thesis.
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2.8.5 Optically Stimulated Luminescent Dosimeters
Recent advances in optically stimulated luminescence dosimeters (OSLDs) have proven
their ability to operate in a mode that allows real-time information about the dose
rate during irradiation. These systems are not yet commercially available, however
a prototype developed by Anderson et al. [58] was examined in order to determine
its ability to identify dose delivery errors in HDR brachytherapy. The system was
capable of measuring absorbed dose rate directly inside the tumour using small OSL
dosimeters fit inside standard needles, with a time resolution of 0.1 seconds. The
combined estimated uncertainty of the system was calculated to be 8% (standard
deviation).
2.8.6 Plastic Scintillation Dosimeters
Plastic scintillation dosimeters (PSDs) have also been considered for IVD of HDR
brachytherapy. They have the added advantage of relative energy independence and
water equivalence when compared with many other dosimeters considered for this
application. Lambert et al. compared PSDs to MOSFET, diamond and TLD detectors
in a phantom study [50]. The study concluded that based on size, accuracy and real-
time possibilities, PSDs showed the best combination of characteristics to perform IVD
in HDR brachytherapy. Cerenkov light production however has also been identified in
the optical guide used in PSD systems [59, 60]. This component, often referred to as
stem effect, is produced in the fibre when struck by electron radiation over a certain
energy threshold, and needs to be removed in order to perform accurate dosimetry. A
number of different methods have been proposed to account for this effect [61, 62].
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2.8.7 Radiofchromic Film
Radiochromic films have not traditionally been considered for IVD of HDR brachyther-
apy treatments. The advantage of radiochromic films over other dosimeters is their
spatial resolution, which is unmatched, as well as the lack of directional dependence.
However, these films require special handling procedures, and a significant amount of
processing before they are able to be analysed. Furthermore, they are unable to be
cut into small pieces (which would allow the films to fit into catheters), as the accu-
racy of the measured dose in regions close to the edge of the film is suboptimal [63].
Consequently, there is only a small amount of published literature on the topic of IVD
for HDR brachytherapy using radiochromic films [64, 65], most of which are related
to skin dose measurements [66, 67].
2.9 Current Methods of High Dose Rate Brachyther-
apy In-vivo Source Tracking
Another, more recently developed method, of performing IVTV in HDR brachytherapy
is in-vivo source tracking. Unlike IVD, where the dose delivered to a detector is placed
within the patient is verified, in-vivo source tracking attempts to track the position
of the HDR brachytherapy source in three-dimensions as it steps through the patient
delivering the treatment. An ideal solution for this method is able to track the source
in real time, verifying both the dwell positions and dwell times, whilst having the
ability to interrupt the treatment if any deviation is found.
2.9.1 Flat Panel Detectors
Smith et al. [68] present the characterization of the response of an a-Si electronic
portal imaging device (EPID) embedded in a customized carbon fibre couch top to an
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Ir-192 HDR brachytherapy source, demonstrating its use as a QA tool and assessing
its potential for use as a HDR brachytherapy source tracking system. Source position
measurements were validated using contact films placed against the catheter during
measurements. All source x and y coordinates were measured to be within 0.5 mm
of the programmed source positions. The mean error across all measurements was
0.01 mm. Smith et al. [69] also directly compared a delivered treatment using the
measured EPID signal against the treatment plan in a phantom study. The EPID
measured dwell positions were directly compared against those predicted by the TPS.
Average dwell position variation was found to be 0.6 mm (S.D. = 0.3 mm and max =
1.4 mm). Fonseca et al. have replicated the work by Smith et al. on a separate EPID
device, achieving similar results [70].
In a further study, Smith et al. retrospectively compared the planned versus mea-
sured source positions using an EPID embedded into the couch for 8 treatment frac-
tions, and the mean linear distance between the planned and measured dwell positions
was found to be 1.8 mm (range 0.7 to 3.9 mm)[71].
2.9.2 Detector Arrays
HDR brachytherapy source tracking has also been demonstrated using 2D diode arrays
[39, 47, 72, 73]. Manikandan et al. first used a commercial 2-D array of ionisation
chambers known as the IMatriXX (IBA, GmBH) and found that with brachyther-
apy catheters placed directly over the array the dwell positions of the Ir-192 source
could be identified to within 1.18 mm [73]. Espinoza et al. further developed this
concept through the use of an 11 x 11 2D diode array (Magic Plate 121, MP121)
packaged in a specially designed Magic Phantom for pre-treatment checks of remote
HDR brachytherapy treatment plan [39].
Espinoza et al. performed a further study, testing the source triangulation algo-
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rithm in combination with the MP121 for 20 catheter treatment plans created by the
Oncentra (Elekta Brachytherapy, Veenendaal, The Netherlands) BTPS [47]. Using the
algorithm, the MP121 was able to accurately track the source position, with 75% of
the measurements falling within 0.5 mm. Dwell times, as well as source transit times
were also determined.
Finally, the MP121 has also been shown to be able to reconstruct source positions
to within 1 mm even when the source is placed approximately 12 & 15 cm away
from the detector plane in a solid water phantom, easily resolving the 2 mm step size
of the source as it moves through the phantom [74]. This final study demonstrates
the potential of the MP121 for in-vivo source tracking in HDR pBT, as this is the
approximate distance the MP121 would be placed away from the source during in-
vivo studies.
2.9.3 Point Detectors
In-vivo source tracking during HDR pBT with point dosimeters has also been exhibited
in the literature through several publications [75, 76, 77]. Johansen et al. demonstrated
this approach through implementation of a single radioluminescent crystal placed into
a dedicated needle during HDR pBT [75]. In this scenario, only radial and longitudinal
shifts of the source relative to planned positions were detected, due to only a single
point detector being used. Rosales et al. also performed source tracking inside a
dedicated needle, this time with a multi-point plastic scintillator dosimeter [77]. For
these experiments three dosimeters were placed inside the dedicated needle for source
tracking of a HDR brachytherapy treatment and achieved a source tracking accuracy
of approximately 1.8 1.6 mm, and a dwell time verification accuracy of less than 0.1
seconds.
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2.9.4 Pinhole Collimator Devices
Pinhole collimator devices have also been used in for source tracking, with several
publications in the literature illustrating this [78, 79, 80]. Safavi-Naeini et al. used a
prototype high resolution pixelated silicon detector array, coupled with a multi-pinhole
tungsten collimator (known as the BrachyView) to track a HDR source in phantom
[78]. The study demonstrated an ability of the BrachyView to track the source to
within 1.3 mm. Alnaghy et al. used the same BrachyView system, this time coupled
with a TRUS probe, to perform HDR source source with simultaneous TRUS image
fusion [79]. In this study, it was shown that the BrachyView was able to resolve dwell
times down to 0.3 seconds, and measure dwell positions to within 1 mm for 78% of
the planned dwell positions in a prostate gel phantom. More importantly however,
coupling of the BrachyView to the TRUS probe also results in a smaller combined
uncertainty when transforming coordinate systems between the BrachyView and the
TRUS probe, which is the imaging device used for treatment planning in real-time
HDR pBT [80].
2.9.5 Electromagnetic Tracking
Electromagnetic tracking (EMT) systems have also shown promise in the field of IVTV
of HDR pBT [81, 82, 83]. Poulin et al. have shown that EMT systems have sufficient
accuracy and precision in brachytherapy theatre environments [82] and Damato et al.
have demonstrated that EMT systems can also detect some common brachytherapy
treatment errors including catheter swaps and reconstruction errors [81]. The EMT
systems have also been incorporated into BTPS for TRUS based HDR pBT and used
for accurate and efficient reconstruction of catheters [83]. Finally, prototype HDR
brachytherapy afterloaders are being produced with EMT systems in-built for the
purpose of catheter reconstruction and transfer tube connection QA [84]. Whilst
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these EMT system show promise for HDR brachytherapy IVTV, there are limitations
of the approach. For example, the source being used to treat the patient is not being
tracked in this approach, and therefore the EMT systems may not be able to detect
all types of errors that may occur in the HDR brachytherapy planning and treatment
process, such as incorrect reference length being used in the BTPS, as well as all dwell
time errors.
Chapter 3
The Geant4 Monte Carlo Toolkit
The Geant4 toolkit is a general purpose C++ based code that was developed by CERN
for high energy particle physics applications. Geant4 is able to simulate the transport
of many types of particles, including the interactions of low energy particles which have
been added in recent years. The toolkit also provides basic functionality of simulation
as to describe detector geometry and materials, to transport particles and to describe
the detector response. This makes Geant4 an attractive tool for the simulation of a
variety of applications in radiotherapy physics, including brachytherapy [85].
Geant4 electromagnetic physics manages the electromagnetic interactions of pho-
tons, electrons, protons and ions over an energy range from 1 eV up to 1000 PeV.
The physics processes that can be modelled in Geant4 include: multiple scattering,
ionization, bremsstrahlung, positron annihilation, photoelectric effect, Compton and
Rayleigh scattering, pair production, synchrotron and transition radiation [85]. There
are two main packages within Geant4 that handle alternative approaches to model the
electromagnetic interaction of particles with matter; the Standard, and Low Energy
Package [86].
The Low Energy Package used in this thesis is able to handle ionization by primary
particles. It handles the interactions of electrons, positrons, photons, charged hadrons
32
3.1. User Action Classes 33
and ions, offering different sets of models for each of the physics processes involved
[86]. Below 1 keV the interactions are described by the free electron gas model, in the
intermediate energy range (between 1 keV and 2 MeV) parameterized models based on
experimental data from the ICRU are used and above 2 MeV the Bethe-Bloch formula
is applied [85].
The Geant4 MC toolkit requires the user to write his or her own C++ program
using classes which inherent behaviour from kernel Geant4 classes [85]. The kernel
Geant4 classes are grouped in independent categories, with defined roles, as shown
in Figure 3.1. The classes which need to be implemented in developing a Geant4
application are described in the following sections.
3.1 User Action Classes
These are virtual classes whose methods control the geometry of the simulation, the
definition of particles, their physics processes, and the generation of primary particles
[86]. They also control the flow of the simulation and allow the retrieval of useful
information concerning track structure, interactions, energy depositions, etc. in the
simulation of the experimental set-up.
3.1.1 G4UserDetectorConstruction
This base class controls the definition of the experimental setup, in terms of geometrical
components and material composition. A geometrical component is defined in terms
of shape, material, positions and rotation in the experimental setup. Visualisation
attributes can be defined at this level, to allow the visualisation of the experimental
setup [86]. In a Geant4 simulation the detector is just a component of the experimental
setup, declared sensitive, where the user can retrieve information about the hits. A
hit is a snapshot of the physical interactions of a track in the sensitive region of the
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detector. The concept of a track represents the physics information (position, energy
deposition, mass, spin, etc.) of the particle under propagation [87].
3.1.2 G4VUserPhysicsList
There are three methods of this class which must be implemented.
The ConstructParticle method defines all particles involved in the experimental
setup. Geant4 provides the implementation of all of the particles defined in the Particle
Data Group Book [86], however the particles involved in the experimental setup of the
simulation must be explicitly invoked in this method [87].
The ConstructProcess method determines the models of interaction for these parti-
cles. All interaction processes are treated in the same manner from the tracking point
of view, this enables the user to create a process and assign it to a particular particle
type. This transparency allows the customization of physics processes by individual
users [87].
The final method is SetCuts which determines the threshold of production of sec-
ondary particles, expressed in range. If a secondary particle is generated with a resid-
ual range in the material less than this value, the particle will not be generated and
tracked, but its energy will be considered locally deposited in the medium. Otherwise,
if the secondary particle energy is greater than the range cut the secondary particle
will be generated and tracked [87].
To support the users, the Geant4 collaboration provides examples of Physics Lists
realised within the toolkit every six months, to be activated directly in the specific
Geant4 application.
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3.1.3 G4VUserPrimaryGeneratorAction
This class allows modelling of the radiation field in the experimental setup of the
simulation, in terms of the type of particle, polarisation, position, direction, energy
and time. The number of primary particles to be generated in one event must also be
defined. An event consists of a collection of primary particles to be tracked [86].
3.1.4 G4VUserEventAction
An event in Geant4 begins with the initiation of tracking one or more primary particles
and finishes with the completion of tracking all secondaries [87]. The G4BUserEventAction
class possesses two virtual methods which are invoked at the beginning and at the end
of each event, the BeginOfEventAction and the EndOfEventAction, respectively.
3.1.5 G4UserRunAction
The concept of a run in Geant4 is to keep a set of events to be simulated using the same
detector geometry, the same event generator and the same physics processes [87]. The
G4UserRunAction class has several methods. One method that is commonly used is
the BeginOfRunAction method which is invoked before entering the simulation event
loop. The second is EndOfRunAction which is invoked at the very end of the event
processing.
3.1.6 G4UserSteppingAction
The concept of a run in Geant4 is to keep a set of events to be simulated using the
same detector geometry. The tracking category manages the propagation of a particle
through the detector taking into account its physics interaction with matter. The
concept of a step in Geant4 describes the transport of a particle between two points
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in space [87]. At this level the user can access information such as energy, position,
direction of the particle, energy deposition, etc.
3.2 Interface Commands
Geant4 has various built-in user interface commands. These commands can be used
interactively via a user interface (GUI), or in batch mode in a macro file. User defined
commands can be implemented in user defined classes, inheriting behaviour from the
G4UIMessenger base class, which represents a messenger that delivers these commands
to a class object [87]. These commands are particularly useful when the geometry,
primary beam, or physics parameters need to be altered between simulations. In this
way, one may execute several simulations using a macro file, containing a number of
suitable commands, to change the experimental setup ad-hoc [86].
3.3 Visualisation
Geant4 has the ability to visualise particle trajectories, detector components and in-
teractions of particles within these detector components [87]. Despite the fact that
there are many methods available for visualisation, the one employed in the simula-
tions described in this thesis is the OpenGL driver. The OpenGL driver is the most
useful for visualising and debugging the detector components as well as the locations
of particle interactions occurring within the geometry.
3.4 Geant4 in the Field of Brachytherapy
Geant4 has been proven to be a trusted tool in the field of brachytherapy in a signif-
icant number of publications over the past decade. Firstly, Geant4 has been used to
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contribute towards the consensus TG43 dosimetry parameters used in the brachyther-
apy dose calculation formalism [4]. Geant4 has also been used to estimate dose to
organs at risk in specific brachytherapy applications such as breast brachytherapy [88]
and eye plaque brachytherapy [89]. Finally, the Geant4 toolkit has also been used
as the dose calculation engine for a clinical brachytherapy treatment planning system
[90]. These are just some of the examples in the literature that demonstrate Geant4
as a proven toolkit for the use of accurate brachytherapy dose calculations.
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Figure 3.1: Schematic of Geant4 toolkit class hierarchy
Chapter 4
A Risk based Approach to
Development of Ultrasound-guided




With the introduction of complex processes, such as TRUS based HDR pBT plan-
ning and delivery, a more intensive and robust QA system is needed. Prescriptive
approaches to HDR brachytherapy QA are provided in the AAPM Task Group Re-
ports 56 [36] and 59 [38]. Williamson [91] reviewed published brachytherapy mis-
administrations in 2008 and found that almost 40% of these were related to: image
Part of this chapter has been published in the Brachytherapy journal: Poder, J, Brown, R, Howie,
A, Yuen, J, Ralston, A, Schreiber, K, Bece, A, & Bucci, J 2018, A risk-based approach to development
of TRUS-based HDR pBT quality management, Brachytherapy, vol. 17, no. 5, pp. 788-93.
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misinterpretation, implanting the wrong organ due to poor image quality, and fail-
ure to verify the needle position. It is therefore beginning to be acknowledged in the
brachytherapy community that prescriptive methods of QM may not be sufficient in
HDR brachytherapy to prevent serious errors in the treatment planning and delivery
process.
Despite its long standing use in industry, the use of failure modes and effects
analysis (FMEA) in radiation oncology has been comparatively recent [2]. Over the
past several years, the number of publications applying FMEA to radiation oncology
has increased dramatically. For EBRT, FMEA has been successfully applied to IMRT
[2], intraoperative radiation therapy [92], stereotactic body radiotherapy [93], amongst
many others.
FMEA has also been shown to be effective for HDR brachytherapy. Swamidas
et al. [94] identified 20 failure modes specific to intracavitary HDR brachytherapy,
including aspects of treatment planning, source strength measurement and applicator
QA. Mayadev et al. [12] also performed FMEA on intracavitary HDR brachytherapy
and found 170 failure modes, the highest ranking of which were applicator instability
and communication failures after patient simulation. Wadi-Ramadi et al. [95]examined
potential failure modes during HDR brachytherapy leading to the incorrect treatment
volume.
The aim of the work presented in this chapter is to apply a risk based approach to
the development of a QM program for TRUS based HDR pBT treatment planning and
delivery using Oncentra Prostate BTPS (Elekta Brachytherapy, Veenendaal, Nether-
lands) [10, 82]. To achieve this aim, an FMEA approach was considered. Detection of
high-risk failure modes in the TRUS based HDR pBT treatment planning and delivery
process allows a tailored approach to the development of QM and identifies whether
there is a need for IVTV through either IVD or source tracking.
4.2. Materials & Methods 41
4.2 Materials & Methods
4.2.1 TRUS Based Real-Time HDR pBT Technique
At St George Hospital Cancer Care Centre (STGCCC), TRUS based HDR pBT
is planned using the Oncentra Prostate BTPS (Elekta Brachytherapy, Veenendaal,
Netherlands). After patient sedation and preparation, the patient is placed in the
dorsal lithotomy position and the TRUS probe (covered by an endorectal balloon) is
inserted by the RO. A 3D US image is then acquired through sagittal rotation of the
probe and the RO contours the prostate, urethra and rectum on the 3D US image.
A 6-mm Foley catheter inserted during patient preparation is visualized on the US
images and used to aid contouring of the urethra. The STGCCC protocol defines the
contours for the rectum and the urethra to extend 10 mm caudally from the apex and
10 mm cranially from the base. The urethra contour also includes the bladder neck,
based on the US visible filled part of the bladder.
Following this, the RO inserts Proguide plastic catheters (Elekta Brachytherapy,
Veenendaal, Netherlands) guided by the live US images, and a physicist simultaneously
identifies only 1 or 2 points of the catheters on the BTPS. A urologist is present to
assist with insertion of the plastic catheters if required.
Table 4.1: DVH metric coverage planning goals used in our institution.






A second 3D US image set is then acquired, and the prostate, urethra and rectum
volumes adjusted accordingly. Final reconstruction of the catheters is performed by
the physicist and RO on the second image set. After reconstruction, the catheter
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tips are adjusted using a manual measurement of the free length of catheter extending
beyond the template [40]. This measurement is checked against the catheter tips in the
BTPS and independently verified using a fluoroscopic image by the radiation therapist.
DVH based inverse optimization is then performed to determine source dwell positions
and times. Dwell positions are activated every 3 mm within the prostate volume. The
DVH based planning aims are shown in Table 4.1. Immediately following planning,
QA checks are performed by the physicist and radiation therapist [40]. The treatment
is delivered with the patient still in the dorsal lithotomy position and TRUS probe in
place. Typical times required for each step in the workflow are given in Table 4.2.
Table 4.2: Time required for each step in the TRUS based real-time HDR pBT work-
flow
Action Typical Time Required
Acquisition of pre-implant 3D TRUS images 5 min.
Contouring of prostate and OARs 10 min.
Implant & identification of all catheters 20 min.
Acquisition of post-implant 3D TRUS images 5 min.
Adaptation of contours onto post-implant image 5 min.
Reconstruction of all catheters 30 min.
Dose prescription & optimization 10 min.
Plan review & approval 5 min.
Quality assurance checks 10 min.
Plan transfer & delivery 10 min.
Total 110 min.
3D = three-dimensional
TRUS = trans-rectal ultrasound
OAR = organ at risk
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4.2.2 Process Map
A process map of the TRUS based HDR pBT planning and delivery process was
developed initially by three physicists, one radiation therapist and two RO’s familiar
with the treatment. Each team member firstly developed their own process map and
identified failure modes at each step in the process. Individual process maps and failure
modes were then discussed and amalgamated at a multi-disciplinary team meeting. In
this analysis, all potential failure modes were considered, regardless of the current QA
program.
4.2.3 Failure Modes and Effects Analysis
Individual team members scored each of the failure modes identified in the process
map according to likelihood of occurrence (O), severity (S) and detectability (D). Each
parameter (O, S, D) was given a score from 1 (less likely to occur, less severe, easy to
detect) to 10 (more likely to occur, more severe, hard to detect) using the AAPM TG
100 formalism [2], as shown in Table 4.3. Scoring for severity was determined using
the descriptions in Table II of the AAPM TG 100 report [2]. Scores for O, S and D for
each failure mode were then multiplied together to give an risk priority number (RPN)
ranking. Finally, RPN rankings for each failure mode were then averaged amongst the
team members.
From the RPN rankings, the multidisciplinary team determined a QM schedule
to minimise risk at each stage of the TRUS based HDR pBT planning and delivery
process and determine the necessity for IVD/source tracking.
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Table 4.3: Scoring of occurrence (O), severity (S) and detectability (D) as per the
AAPM TG 100 formalism [2].
Rank Occurence (O) Severity (S)
Detectability
(D)





































































4.3.1 Ultrasound based high dose rate prostate brachyther-
apy process map
During process mapping, 7 major processes in the TRUS based HDR pBT planning
and delivery process were identified, as shown in Figure 4.1. This major process map
was then used to identify minor processes, from which an FMEA was performed to
identify potential failure modes during each minor process.
Figure 4.1: Major process map for ultrasound based HDR pBT planning and delivery.
4.3.2 Failure Modes and Effects Analysis based Quality Man-
agement
From the FMEA, the authors identified 35 potential failure modes within the 7 major
processes shown in Figure 4.1. A full list of potential failure modes sorted according to
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rank are presented in Table 4.4. The failure mode with the highest RPN was identified
to be mislabelling of catheters/incorrect transfer tube connected. The failure mode
with the highest occurrence (O = 8) was the US grid settings being changed. This
failure mode was ranked 13th overall though according to RPN due to its relatively
high detectability. The failure mode with the highest severity (S = 9) was the incorrect
source details being entered into the BTPS/afterloader. This failure mode ranked 2nd
overall according to RPN. Finally, the failure mode with the lowest detectability (D =
8) was the error in drive cable positioning during patient treatment. This failure mode
was ranked 3rd overall according to RPN. Only 2 potential failure modes (5.4%) had
an average RPN greater than 200, 21 (55.3%) had an average RPN between 100-200
and 15 (39.0 %) had an average RPN between 0-99. Potential failure modes with the
highest RPN were observed to have high severity (S >7) and low detectability (D >6),
but low occurrence (O >6).
Table 4.4 also summarises which failure modes would potentially be detectable by
IVTV. As can be seen from Table 4.4, IVTV is able to detect 25/35 (71%) of identified
failure modes, including 9/10 (90%) of the 10 highest ranked failure modes.
Table 4.4: Failure modes identified during FMEA process, ranked according to RPN.






5 7 7 245 Yes
2 Incorrect sources details in
BTPS/afterloader
4 9 6 216 Yes
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3 Error in drive cable posi-
tioning during patient treat-
ment
4 6 8 192 Yes
4 Incorrect reconstruction of
catheter points due to imag-
ing artefacts
6 6 5 180 Yes
5 Incorrect OAR contour 5 6 6 180 No
6 Error in TRUS stepper dis-
tance encoder calibration
5 5 7 175 Yes
7 Error in TRUS stepper ro-
tation encoder calibration
4 6 7 168 Yes
8 Incorrect catheter free
length used in BTPS
3 8 7 168 Yes
9 Incorrect distance from
template to TRUS trans-
ducer entered into BTPS
4 7 6 168 Yes
10 TRUS grid not locked after
insertion of catheters
4 6 7 168 Yes
11 Incorrect target contour 5 6 5 150 No
12 Entire prostate not in final
volume acquisition
5 6 5 150 No
13 TRUS grid settings changed 8 6 3 144 Yes
14 Coordinate system origin
not set/set incorrectly in
BTPS
5 7 4 140 Yes
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15 Catheters shifted in time
between volume scan and
treatment
4 7 5 140 Yes
16 Perforation of ure-
thra/rectum during
catheter insertion
4 7 5 140 No
17 Incorrect reference length
entered into BTPS
5 7 4 140 Yes
18 Incorrect prescription dose
entered into BTPS
3 9 5 135 No
19 DVH grid used for plan as-
sessment too coarse
3 6 7 126 No
20 Incorrect grid position se-
lected during catheter re-
construction
5 5 5 125 Yes
21 TRUS probe removed be-
fore treatment
5 6 4 120 Yes
22 Catheter tips not visible in
final volume acquisition
5 5 4 100 Yes
23 Incorrect reconstruction
due to complex catheter
placement
4 6 4 96 Yes
24 Inability to detect catheter
during reconstruction due
to shadowing
5 6 3 90 Yes
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25 TRUS image settings
changed
7 4 3 84 Yes
26 Suboptimal optimisation
due to not applying changed
after manual optimisation
4 6 3 72 No
27 Poor image quality due
to poor contact between
TRUS and rectal wall
5 5 2 50 Yes
28 Plan/DVH assessment set-
tings changed in BTPS
3 7 2 42 No
29 Poor connection between
transfer tube and catheter
7 3 2 42 Yes
30 Incorrect date/time in
BTPS
2 4 5 40 Yes
31 Incorrect optimisation pa-
rameters used in BTPS
4 5 2 40 No
32 Incorrect normalisation
mode
3 5 2 30 No
33 Manual dwell activation
causes change in normalisa-
tion
3 5 2 30 Yes
34 Faulty cables/connectors 5 3 2 30 Yes
35 TRUS/stepper cradle
lost/broken





RPN = risk priority number
IVTV = in-vivo treatment verification
BTPS = brachytherapy treatment planning system
OAR = organ at risk
TRUS = transrectal ultrasound probe
DVH = dose volume histogram
Based on the FMEA a QM checklist (Table 4.5) was developed with the aim to
reduce the occurrence and increase the detectability of the failure modes presented in
Table 4.4. The QM checklist was also developed to ensure that the efficient nature
of the TRUS based HDR pBT planning and treatment process is maintained, due
to the time pressures associated with performing the procedure whilst the patient is
anesthetised. The used of this QM checklist in combination with some form of IVTV
will result in a significant reduction of risk of mistreatment during TRUS based HDR
pBT.
Table 4.5: QM checklist developed for TRUS based HDR pBT treatment planning
and delivery.
Pre-Treatment QA
2 Afterloader daily QA completed
2 TRUS stepper rotation and distance encoder calibration checked
2 TRUS and BTPS grid settings checked
2 Source strength details entered into BTPS and cross-checked
2 Patient details entered into BTPS and cross-checked
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2 Patient consent completed
2 Patient time out completed
Pre-Implant 3D Image Acquisition
2 All stepper motions and track are locked
2 TRUS grid covers entire expected implant geometry
2 Prostate base plane and origin set correctly
2 Image quality and volume coverage acceptable in sagittal view
Contouring
2 Prostate and OAR contours delineated accurately
2 Base, reference, and apex planes set according to prostate contour
Prescription
2 Check and apply correct prescription
2 Ensure correct source selected
Catheter Insertion
2 All catheters inserted by radiation oncologist, catheter positions correctly identi-
fied in BTPS
2 All catheters reconstructed on live TRUS images
2 All catheters pushed to appropriate depth (tips visible on sagittal image)
2 Obturators removed, template locked
2 Fluoroscopic image taken with CT markers, measure catheter tip distance beyond
base fiducial
Post-Implant 3D Image Acquisition
2 Prostate base plan and origin set correctly




2 All pre-implant contours imported
2 All contours modified on post-implant acquisition if required
Catheter Reconstruction
2 Catheters reconstructed accurately in all three views (sagittal, axial, coronal)
2 Catheters free lengths measured, cross-checked and entered into BTPS
2 Catheter tip QA performed
Dose Optimisation
2 Inverse optimisation performed
2 Graphical optimisation performed if necessary
Plan Evaluation
2 Isodose and DVH reviewed by radiation oncologist
2 Plan approved
Independent Plan Check
2 Point doses checked in independent plan check software
2 Contours are acceptable
2 Catheters reconstructed accurately
2 Catheter orientation is correct
2 Catheter reference length is correct
2 Activated dwell positions are within prostate volume + margin
2 Correct source details are selected
2 Treatment plan date/time is correct
2 Prescription as per protocol
2 Prostate coverage as per protocol
2 Prostate high dose regions as per protocol
2 Organ at risk doses as per protocol
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Plan Transfer & Delivery
2 Transfer tubes connected to corresponding numbered catheters and connections
cross-checked
2 Plan exported to afterloader
2 Source details correct in afterloader
2 Cross-check of dwell times and positions between BTPS and afterloader
2 Shielding in place next to afterloader 2 All staff out of theatre, treatment initiated
QA = quality assurance TRUS = transrectal ultrasound probe
BTPS = brachytherapy treatment planning system
3D = three dimensional OAR = organ at risk
4.4 Discussion
From the analyses, 7 potential risks/failure modes were found to be related to the
catheter reconstruction major process. Furthermore, the catheter reconstruction major
process was also found to have the highest average ranked potential failure modes
according to RPN. This is largely due to the difficulty in visualising the catheters on
the US images, especially towards the catheter tips. To minimise the potential for
error in catheter tip identification, a catheter tip check was incorporated into the QM
checklist shown in Table 4.5, similar that developed by Zheng & Todor [96].
The FMEA identified a number of potential risks that would not have been consid-
ered if following prescriptive QA recommendations in consensus guidelines [36, 38, 97].
For example, risks/failure modes related to catheter tip location and catheter recon-
4.5. Conclusion 54
struction. This underscores the advantage of performing risk based analysis when
introducing a new technique/technology in the radiation oncology environment, par-
ticularly because each department will likely follow individualised workflows that in-
herently have unique risks/failure modes.
One limitation of this study is the subjective nature of the risk based approaches,
especially when performing scoring for the likelihood of occurrence, severity, and de-
tectability. However, at a minimum the risk based analysis ensures a holistic review
of the entire QM program and ranking of potential failure modes according to RPN
results in team members focusing the QM towards the most dangerous parts of the
process.
The FMEA also highlights the potential advantage of performing IVTV, with 9/10
of the highest risk failure modes being detectable by some form of IVTV. Whilst a
comprehensive QM checklist will minimise the risk associated with the TRUS based
HDR pBT planning and treatment process, it is likely to be inevitable that subopti-
mal treatments may still be delivered. Therefore, when combined with a QM checklist,
IVTV will provide an additional safeguard against potential mistreatments when de-
livering TRUS based HDR pBT treatments.
4.5 Conclusion
FMEA was shown to be a valuable tool in developing a QM program for TRUS based
HDR pBT treatments. Many potential failure modes were identified that were not
previously considered when following international consensus QA recommendations
for HDR pBT. Furthermore, a considerable number of the potential failure modes
identified were related to human or procedural errors, highlighting the importance of
checklists and IVTV in delivering a safe and effective TRUS based HDR pBT treat-
ment. Future chapters of this thesis will further examine the feasibility of performing
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IVTV during TRUS based HDR pBT to supplement the QM checklist developed in
this chapter.
Chapter 5
In-vivo Source Tracking Error
Thresholds for Ultrasound Based
HDR Prostate Brachytherapy
5.1 Introduction
Due to the increased awareness of risks associated with brachytherapy treatments like
those described in the previous chapter, there has been an increased focus amongst the
brachytherapy community in recent years towards more in-vivo treatment validation
(IVTV). One aspect of this focus has been on the use of several detector types for IVD
in HDR brachytherapy [56, 98, 75]. Another form of IVTV has been real-time in-vivo
source tracking, through the use of either 2D detector arrays [99, 100, 70, 101], or single
point detectors [75, 102, 103]. In-vivo source tracking techniques using 2D arrays have
been shown to have the ability to track the brachytherapy source to within 1.9 mm
Part of this chapter has been published in the Brachytherapy journal: Poder, J, Carrara, M,
Howie, A, Cutajar, D, Bucci, J & Rosenfeld, A 2019, Derivation of invivo source tracking error
thresholds for TRUS based HDR pBT through simulation of source positioningerrors, Brachytherapy,
vol. 18, no. 5, pp. 711-9.
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relative to the patient anatomy [99, 100, 70, 101], whilst point detectors placed within
a catheter have measured shifts in dwell positions (relative to the detector) on the
order of 0.5 mm [75]. There has, however, been no published studies demonstrating
the minimum source positioning error that must be resolved by source tracking devices
in order to detect potentially clinically significant changes in dose distributions around
the target and surrounding OARs.
The purpose of this chapter is to simulate source positioning errors in TRUS based
real-time HDR pBT and determine appropriate in-vivo source tracking action thresh-
olds so that clinically significant changes in the delivered dose distributions might be
prevented. Error thresholds calculated in this chapter will serve as a benchmark to
determine the feasibility of performing in-vivo source tracking during TRUS based
real-time HDR pBT using a the Magic Plate (MP) diode array in future chapters of
this thesis.
5.2 Materials & Methods
5.2.1 Patient and Treatment Characteristics
Twenty patients who have previously been treated with a HDR pBT boost in the period
of 2016-2018, in combination with EBRT were randomly selected for this study. The
HDR pBT boost was delivered as 2 fractions of 9 Gy delivered 1 week apart, with the
aim to deliver 18 Gy to the target volume using an Ir-192 source. The HDR pBT boost
was delivered prior to the EBRT component of the treatment, which aimed to treat
the whole pelvis with a prescription of 46 Gy in 23 fractions. The TRUS based HDR
pBT technique used to treat the patients is described in section 5.2.1 of this thesis.
Characteristics of the patients prostate volumes, and treatment plans are shown in
Table 5.1..
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Table 5.1: Characteristics of the patient plans considered in this study.
Characteristic Average (min-max)
Prostate volume (cc) 39.9 (23.2 68.7)
Number of catheters 19 (17 25)
TRAK (Gy.m2) 3.4 (2.6 4.7)
Percentage weight of 3 most heavily weighted
catheters (%)
30.9 (23.3 37.8)
Prostate (D90%) 106.5 (104.0 109.1)
Prostate (V100%) 97.6 (96.4 98.6)
Prostate (V150%) 20.1 (15.8 24.0)
Prostate (V200%) 4.1 (1.8 6.9)
Urethra (D1cc) 116.3 (111.9 119.3)
Rectum (D2cc) 63.4 (57.9 69.0)
5.2.2 Simulated Treatment Planning Source Positioning Er-
rors
Treatment planning source positioning errors were simulated in the BTPS by manually
adjusting the dwell position coordinates within the selected catheters without plan re-
optimization. A previous study by the STGCCC team identified high risk failure
modes in the TRUS based HDR pBT process, which can result in two distinct types
of treatment planning source positioning error [40].
The first type of treatment planning source positioning error results in the actual
source dwell positions being shifted in the cranial or caudal direction relative to the
planned source dwell position. Examples of the causes of these errors include: incor-
rect catheter indexer length used in BTPS, incorrect catheter free length entered into
BTPS, and BTPS coordinate system origin not set correctly. Source positioning errors
of this type were simulated in this study from -6 mm (caudal) to +6 mm (cranial) in
1 mm increments.
The second type of treatment planning source positioning error considered in this
study results in source dwell positions being shifted in the anterior/posterior or me-
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dial/lateral directions relative to planned source dwell positions. Examples of the
causes of these errors include: incorrect reconstruction of catheter points due to imag-
ing artefacts, incorrect grid position selected for catheter reconstruction, and inability
to detect catheter during reconstruction due to shadowing. Source positioning errors
of this type were simulated in this study from -6 mm (posterior/medial) to +6 mm
(anterior/lateral) in 1 mm increments. A previous study be Rylander, et al. identified
that a median of 3 catheters per plan require correction, with catheter reconstructions
errors in the range from 0 to 9.6 mm [104].
In this study two types of anterior/posterior or medial/lateral treatment planning
source positioning error scenarios were assumed. The first scenario assumed source
positioning errors from the 3 most heavily weighted catheters in the plan were all in the
same direction, e.g. all 3 catheter source positioning errors simulated in the posterior
direction. Figure 5.1 shows the frequency of the position for the three most heavily
weighted catheters across all of the patients considered in this study, superimposed
with a typical prostate contour (red), urethra contour (yellow), and rectum contour
(brown) at the mid-prostate slice. The second scenario assumed treatment planning
source positioning errors from the 3 catheters closest to the urethra and the rectum
in the direction towards the OAR, e.g. source positioning errors for the 3 catheters
closest to the urethra, moving towards the urethra.
5.2. Materials & Methods 60
Figure 5.1: Frequency of the position for the three most heavily weighted catheters
across all of the patients considered in this study, superimposed with a typical prostate
contour (red), urethra contour (yellow), and rectum contour (brown) at the mid-
prostate slice.
5.2.3 Plan Analysis
All patient plans were assessed by evaluating the DVH indices outlined in Table 5.1.
The change in the DVH indices was then calculated as a function of the magnitude
of source positioning errors outlined above. The change in these indices with increas-
ing magnitude of source positioning error gives an indication of the suitable in-vivo
source tracking action thresholds that should be applied to prevent clinically significant
changes in DVH indices.
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5.3 Results
The change in DVH indices for the prostate volume as a function of treatment plan-
ning source positioning errors are shown in Figure 5.2. For the cranial/caudal direction
(Figure 5.2a) all prostate DVH indices were found to be more sensitive to source posi-
tioning errors in the cranial direction than the caudal direction. Each of the prostate
DVH indices showed little variation with increasing magnitude of source positioning
errors in the anterior-posterior direction (Figure 5.2b). However, for the medial-lateral
direction (Figure 5.2c the prostate DVH indices were found to be more sensitive to
source positioning errors in the lateral direction, relative to the medial direction. For





Figure 5.2: a) Average change in DVH metrics (±2 standard deviation (SD)) for the
prostate contour as a function of source positioning errors in the cranial-caudal di-
rection (all catheters), b) the anterior-posterior direction (3 most heavily weighted
catheters), and c) the medial-lateral direction (3 most heavily weighted catheters).
Negative values in source positioning error correspond to the caudal, posterior and
medial directions. Positive values correspond to the cranial, anterior and lateral di-
rections.
Figure 5.3 shows the percentage of patients considered in this study that fail the
prostate V100% DVH planning aim (V100% >95%) as a function of source positioning
error for all three directions. The results support the data presented in Figures 5.2 a) -
c) where the source positioning errors in the cranial-caudal direction are more sensitive
than those in the anterior-posterior and medial-lateral directions. For the cranial and
caudal directions, 75% and 50% of the patients in this study fail the prostate V100%
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planning aim for a 3 mm shift respectively, whilst 0%/5% fail for a 3 mm shift in the
posterior/anterior directions and 35%/10% fail for a 3 mm shift in the medial/lateral
directions.
The percentage of patients failing the prostate V100% DVH planning aim increases
significantly when the source positioning error becomes greater than 2 mm in the
cranial/caudal direction. This is likely due to the 3 mm step size used in treatment
planning. As source positioning errors reach 3 mm in the cranial/caudal direction,
dwell positions begin to move outside of the prostate volume, having a more significant
effect on the prostate V100% DVH metric.
For the medial/lateral and posterior/anterior source positioning errors the shape
of the curves in Figures 5.2 and 5.3 are governed by the position of the 3 most heavily
weighted catheters within the plan, relative to the anatomy. As can be seen in Figure
5.1, the 3 most heavily weighted catheters often occur in the central region of the
prostate (rows 2-3 and columns C-E). Movement of these catheters laterally, results in
cold spots in the central region of the prostate. The effect of moving these catheters
either anteriorly or posteriorly however is minimal.
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Figure 5.3: Percentage of patients whose plans would fail according to the prostate
V100% DVH planning aim (V100% >95%) as a function of source positioning error
for all three directions. Negative values in source positioning error correspond to the
caudal, posterior and medial directions. Positive values correspond to the cranial,
anterior and lateral directions.
The change in DVH indices for the OARs as a function of treatment planning
source positioning errors are shown in Figure 5.4. The urethra D1cc was observed to
be more sensitive than the rectum V70% for source positioning errors in the caudal,
anterior, and medial directions. The sensitivity of the urethra D1cc was similar to
the rectum V70% in the cranial, posterior, and lateral directions. The urethra D1cc
was more sensitive to source positioning errors in the cranial direction than the caudal
direction (Figure 5.4a. Conversely, the rectum V70% has the same sensitivity to
source positioning errors in both the cranial and caudal directions. As expected, the
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rectum V70% was most sensitive to source positioning errors in the posterior direction
relative to the anterior direction (Figure 5.4b, and the urethra D1cc was most sensitive
to source positioning errors in the medial direction relative to the lateral direction
(Figure 5.4c. The sensitivity of the urethra D1cc to source positioning errors in all
directions was again observed to have a significant amount of variation amongst the
cohort of patients in the study.
(a) (b)
(c)
Figure 5.4: a) Average change in DVH metrics (±2 SD) for the urethra and rectum
contours as a function of source positioning errors in the cranial-caudal direction (all
catheters), b) the anterior-posterior direction (3 most heavily weighted catheters), and
c) the medial-lateral direction (3 most heavily weighted catheters). Negative values
in source positioning error correspond to the caudal, posterior and medial directions.
Positive values correspond to the cranial, anterior and lateral directions.
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Figures 5.5a and 5.5b show the percentage of patients whose plans would fail ac-
cording to the urethra D1cc DVH planning aim (D1cc <120%) and the rectum D2cc
DVH planning aim (D2cc <70%) as a function of source positioning error for all three
directions. The urethra again was found to be most sensitive to source positioning
errors in the medial, anterior and posterior directions, with a 2 mm source positioning
error resulting in a violation of the urethra D1cc planning aim for more than 50% of
patients. The rectum was again observed to be less sensitive to source positioning
errors, with only a 5 mm error in the posterior direction resulting in a violation of the
rectum D2cc planning aim for more than 50% of the patients.
The percentage of patients failing the urethra D1cc DVH planning aim increases
significantly when the source positioning error reaches 1 mm in the medial, anterior,
and posterior directions. This can be attributed to the proximity of the 3 most heavily
weighted catheters in the plan to the urethra (Figure 5.1). In contrast, the 3 most
heavily weighted catheters are a significant distance from the rectum, and source




Figure 5.5: a) Percentage of patients whose plans would fail according to the urethra
D1cc DVH planning aim (D1cc <120%) as a function of source positioning error for
all three directions, b) Percentage of patients whose plans would fail according to the
rectum D2cc DVH planning aim (D2cc <70%) as a function of source positioning error
for all three directions. Negative values in source positioning error correspond to the
caudal, posterior and medial directions. Positive values correspond to the cranial,
anterior and lateral directions.
Figure 5.6 presents the second anterior/posterior or medial/lateral source position-
ing error scenario where source positioning errors from the 3 catheters closest to the
urethra and the rectum in the direction towards the OAR. As was the case for the
first scenario, where source positioning errors in the 3 most heavily weighted catheters
were assumed, the urethra was again more sensitive to source positioning errors than
the rectum. As can be seen in Figure 5.2b, only a 2 mm source positioning error is
required before more than 50% of the patients result in a failure of the urethra D1cc
planning aim, whilst a 4 mm source positioning error is required for the rectum.
This difference can be attributed to the catheters located close to the urethra being
more heavily weighted than those close to the rectum, as can be seen in Figure 5.1.
Additionally, from the OAR to the 3 closest catheters is less for the urethra than for
the rectum. Therefore, the proximity, as well as the weight of the catheters closest to




Figure 5.6: a) Average change in DVH metrics (2 SD) for the urethra and rectum
contours as a function of source positioning errors towards the OAR. b) Percentage
of patients whose plans would fail according to the urethra D1cc DVH planning aim
(D1cc <120%) and the rectum D2cc DVH planning aim (D2cc <70%) as a function
of source positioning error towards the OAR.
5.4 Discussion
Whilst the sensitivity of the DVH parameters to source positioning errors has been
derived in this study, the question still remains as to what level the action threshold
should be set for in-vivo source tracking devices to prevent clinically significant changes
in the delivered dose distributions. According to Hoskin, et al. [105] both the prostate
D90% and V100% are significant predictors for biochemical relapse in intermediate and
high risk patients treated with HDR pBT boost. The study demonstrates that a 5%
decrease in either the prostate D90% or V100% corresponds to a 10% increase in the
risk of biochemical relapse. Considering source positioning errors in the cranial/caudal
direction, from Figure 5.2a, this 5% change is represented by the red dashed lines. It
can be seen from the figure that a 5% change in the prostate D90% and V100% occurs
with source positioning errors of approximately 3 mm. Additionally, from Figure 5.3
the percentage of patients failing the prostate V100% DVH planning aim increases
significantly when the source positioning error reaches 2 mm in the cranial/caudal
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Consequently, a 2 mm source positioning error in the cranial/caudal direction may be
an appropriate action level for in-vivo source tracking during HDR pBT to decrease
the risk of potential biochemical relapse.
Again, considering source positioning errors in the cranial/caudal direction, from
Figure 5.2b it can be seen that the urethra D1cc is more sensitive than the rectum
D2cc to source positioning errors of this type. This is supported by the clinical ev-
idence, where acute urinary symptoms and erectile dysfunction are more commonly
reported than rectal complications in patients treated with HDR pBT in combination
with EBRT [106]. Given the extreme heterogeneity in dose fractionation schedules
published in the literature with excellent results, there has been no established dose-
volume relationship between risk of normal tissue complication and DVH indices for
the urethra and rectum in HDR pBT. Therefore, for the purpose of this study a 5%
change in the urethra D1cc was considered as a clinically relevant change in the deliv-
ered dose distribution. Applying this threshold in Figure 5.2b a 5% change in D1cc for
the urethra occurs for source positioning errors of 3-4 mm. From Figure 5.5a a source
positioning error of 3 mm results in 35% of patients considered in this study failing
their urethra D1cc DVH planning aim. Therefore, an action threshold of a 3 mm source
positioning error in the cranial/caudal direction should be applied when performing
in-vivo source tracking in HDR pBT to prevent normal tissue complications.
For the prostate DVH metrics, treatment planning errors of the 3 most heavily
weighted catheters in the medial/lateral direction were found to have similar sensitiv-
ity to those for all catheters cranial/caudal direction, with an in-vivo source tracking
error threshold of 3 mm appearing to be appropriate. The sensitivity of the DVH
metrics to source positioning errors of the 3 most heavily weighted catheters in the
anterior/posterior direction however was observed to be weaker than the other direc-
tions, where for almost all patients in the study errors of up to 6 mm still resulted in
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less than 5% change in prostate V100% and D90%.
Treatment planning source positioning errors for 3 the most heavily weighted
catheters in the anterior/posterior and medial/lateral directions as related to the OARs
are more complex for all catheters in the cranial/caudal direction. Due to the nature of
the catheter implant pattern around the urethra and anterior to the rectum, the effect
of the treatment planning source positioning errors in these directions on the dose to
the OARs is highly patient dependent. For example, one patient from this study had
a 31% increase in the urethra D1cc for the 3 most heavily weighted catheters moving
4 mm in the medial direction, whereas another patient only had an increase of 5%.
The relationship between the change in the OAR DVH and the magnitude of source
positioning error is therefore considerably complex, dependent on the proximity of the
catheter to the OAR, along with the weighting of the catheter within the plan.
This study assumes two scenarios: 3 most heavily weighted catheters having source
positioning errors in the same direction, and 3 catheters closest to the OAR (ure-
thra/rectum) having a source positioning error towards the OAR. Consequently, the
magnitude of the change in delivered dose distributions reported in this study due to
source positioning errors may be considered clinically relevant and may even be biased
towards a conservative estimate. However, it is difficult to draw any definitive con-
clusions on appropriate treatment planning source positioning error thresholds in the
anterior/posterior and medial/lateral directions for in-vivo source tracking to prevent
clinically significant changes in dose distributions to OARs. However, one conclusion
that may be interpreted from the OAR results is that the urethra is much more sensi-
tive to source positioning errors than the rectum, due to the increased weighting and
the proximity of the catheters around the urethra in the treatment plans considered in
this study. It may therefore be prudent to limit the weighting of individual catheters
during the optimization process to improve the robustness of HDR pBT treatment
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plans to source positioning errors, subsequently easing the burden on in-vivo source
tracking devices.
In this study, the sensitivity of DVH indices to treatment planning source position-
ing errors was observed to be directionally dependent. Consequently, when performing
in-vivo source tracking during HDR pBT, action thresholds for source positioning er-
rors may potentially be set independently for each direction. This is a significant
finding in the context of in-vivo source tracking where it has been shown previously
that source tracking accuracy using 2D arrays in the anterior-posterior direction is sub-
optimal relative to the cranial/caudal and medial/lateral directions [99, 100, 101, 69].
If a larger action threshold can be set in the anterior-posterior direction, the sensitivity
and specificity of the source tracking device can be improved.
Previous studies investigating the robustness of HDR pBT plans to catheter mis-
placements have also suggested tolerances of 2-3 mm as an error threshold for the
difference between planned and delivered dwell positions [107, 108].
One limitation of this study is that only treatment planning source positioning
errors are considered. However this is not the only error type that may occur in TRUS
based real-time HDR pBT. For example, there have been several publications in the
literature demonstrating the systematic migration of the catheter implant relative to
the anatomy, in the time between imaging and treatment [56, 57, 109, 110]. This
type of error is especially relevant when attempting in-vivo source tracking with point
detectors placed within catheters [75, 103, 102], as the migration of catheter in which
the detector is placed, relative to the other catheter from the implant will negatively
affect the source tracking accuracy of the device. Reported catheter migration for
stainless steel catheters ( 1 mm) [109] is less than that reported for plastic catheters
(up to 8 mm) [57]. Consequently, the use of stainless steel catheters may not only aid
in minimization of reconstruction errors, but also minimization of catheter migration
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in the time between imaging and treatment.
Additionally, as reported by Milickovic et al. [109], there is also potential for not
only the catheters to migrate in the time between imaging and treatment, but also
the patient anatomy (e.g. due to prostate oedema). In some instances, movement of
the anatomy may occur in the same direction and with the same magnitude as the
catheters, and the DVH indices will not be effected by the catheter migration [109].
This presents a unique problem with respect to in-vivo source tracking, as a treatment
error may be identified by the source tracking system due to catheter migration away
from the planned positions, when in fact no clinically significant change to the dose
delivered to the prostate and OARs will have occurred. Therefore, it is necessary
to confirm the position of both the patient anatomy and catheters within the BTPS
coordinate system immediately prior to treatment. Previous studies utilising EMT
systems for catheter reconstruction have exhibited an increase in both accuracy and
efficiency of catheter reconstruction, confirming its potential for both direct catheter
reconstruction in the BTPS as well as for confirmation of catheter position immediately
prior to treatment [83, 82, 81]. Combining the EMT system for catheter reconstruction
& confirmation of catheter position prior to treatment with a source tracking device
such as the MP may allow for the realisation of a comprehensive in-vivo QA system
for real-time TRUS based HDR pBT capable of detecting almost all error types.
Finally, the question of at which point should a treatment be interrupted using
a real-time in-vivo source tracking device? also remains unanswered. For example, if
three successive dwell positions were found to have a source positioning error of greater
than 3 mm, should the treatment be interrupted? The answer is that it is dependent
on the weight of the dwell position, its proximity to an OAR, as well as multiple other
factors related to the plan and patient anatomy. Therefore, in order to implement
appropriate real-time in-vivo source tracking error thresholds, some prior information
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about the context of the dwell positons within the treatment plan may be required.
This issue may be superseded however, through the use of the source tracking device
to interface with both the BTPS and the brachytherapy afterloader to perform online
adaptive HDR brachytherapy treatments.
5.5 Conclusion
In this chapter, in-vivo source tracking error thresholds for TRUS based real-time
HDR pBT are investigated via the simulation of treatment planning source position-
ing errors and were found to be directionally dependent. Error thresholds in the
anterior/posterior and medial/lateral directions for the prevention of normal tissue
complications were found to be complex and patient dependent, requiring further
investigation beyond the scope of this study. Finally, it should be noted that the pro-
posed in-vivo source tracking error thresholds in the order of 2-3 mm proposed in this
study are an estimate, and that there is still the potential for larger changes in DVH
indices to occur for catheter shifts smaller than the proposed threshold levels. Future
chapters of this thesis will aim to determine whether in-vivo source tracking using the
MP 2D diode array will have sufficient accuracy to detect the clinically relevant source
positioning errors identified in this chapter.
Chapter 6
Ir-192 Flexisource TG-43 Monte
Carlo Simulations
6.1 Introduction
Future chapters of this thesis will present Monte Carlo (MC) simulations of HDR
pBT, including the response of the MP) 2D diode array embedded into the patient
couch.
Before using a MC model of an Ir-192 source in the simulation of HDR brachyther-
apy treatments, the Ir-192 source model must first be validated against benchmark
data. The purpose of this chapter is to perform MC simulations of the AAPM TG43
parameters [9, 3, 31] of the Ir-192 source used in the Flexitron afterloading system
(Flexisource, Elekta Brachytherapy, Veenendaal, The Netherlands). The two spe-
cific TG43 parameters that will be studied are the radial dose function and the 2D
anisotropy of the source. MC simulations used in the chapter will be performed using
Part of this chapter has been published in the Journal of Applied Clinical Medical Physics: Poder,
J, Cutajar, D, Guatelli, S, Petasecca, M, Howie, A, Bucci, J & Rosenfeld, A 2018, HDR brachytherapy
in vivo source position verification using a 2D diode array: A Monte Carlo study, Journal of Applied
Clinical Medical Physics, vol. 19, no. 4, pp. 163-72.
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the Geant4 simulation toolkit (v4.10.01) [86, 111], as described in Chapter 3.
6.2 Materials & Methods
6.2.1 Ir-192 Flexisource Model
The geometric design of the Flexisource model was obtained from the study performed
by Granero et al. [4] and is shown in Figure 6.1. The Ir-192 core is modelled as a pure
Iridium cylinder of length 3.5 mm and diameter 0.6 mm. It has a physical density of
22.42 g/cm3 and is placed at the geometric centre of the simulation volume.
Figure 6.1: Geometric design of the Flexisource Ir-192 HDR source [4].
The active Ir-192 core is surrounded by a stainless steel shell of length 4.6 mm, 0.85
mm outer diameter and inner diameter of 0.67 mm. This results in a shell thickness of
0.09 mm. The composition by weight of the stainless steel shell is modelled as follows:
Fe 67.92%, Cr 19%, Ni 10%, Mn 2%, Si 1% and C 0.08% and the physical density
is 7.999 g/cm3. The non-cable end weld of the stainless steel shell is modelled as a
cylinder of length 0.65 mm and diameter 0.85 mm. The cable end weld of the stainless
steel shell is modelled as a partial cone of maximum diameter 0.85 mm, minimum
diameter of 0.5 mm and length 0.4 mm. Finally, the stainless steel cable is modelled
as a cylinder of 5 mm length and 0.5 mm diameter, as recommended by Granero et
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al. [4]. The space between the outer stainless steel shell and the inner Iridium core
was modelled as dry air with a physical density of 1.20 mg/cm3.
The spectrum of gamma energies emitted from the Ir-192 source was obtained from
the NuDat database [1]. The β spectrum was not considered in the study since its
contribution to the dose delivered beyond the stainless steel shell is negligible [4].
6.2.2 Phantom Geometry
The AAPM TG43-U1 report [3] recommends that MC simulations used to obtain
TG43 parameters be performed with the source placed in the centre of a spherical 80
cm diameter water phantom, so as to simulate an unbounded phantom [112]. The
phantom geometry used in this simulation is an 80 cm length square box phantom
made from liquid water with physical density 0.998 g/cm3. The density of 0.998g/cm3
was chosen so as to simulate the density of liquid water at 22°C as is recommended in
TG43-U1 [3].
6.2.3 Physics Modelling
The interaction processes for photons (the photoelectric effect, Compton scattering
and Rayleigh scattering) are modelled using the Geant4 Livermore low energy package.
The interactions cross-sections tabulation is taken from the EPDL97 database [113].
In order to improve the efficiency of the simulations, the linear track-length kerma
estimator [114] was utilised with a photon cut-off energy of 250 eV. Secondary particles
with range less than 0.1 mm are assumed to deposit the dose locally in the interaction
voxel.
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6.2.4 Dose Scoring
To obtain the dose rate in polar coordinates and calculate the TG43 parameters, the
dose is scored in concentric spherical sections with thickness of 0.5 mm (from 0 to
20 cm) and angular resolution of 1°(from 0°to 180°), as shown in Figure 6.2. The
thickness and resolution of the voxels were chosen so as to ensure the effect of volume
averaging is less than 0.1% for distances greater than 5 mm from the source [115]. In
order to calculate the absorbed dose in each of the spherical sections the total energy
deposited in each section is obtained and divided by the total mass of the section.
Figure 6.2: Top-down schematic view of the concentric spherical shells (in black)
around the Ir-192 source (in red) used for dose scoring. Image is not to scale.
The longitudinal axis of the source is located along the z axis of the coordinate
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system with the centre of the Ir-192 source placed the geometric centre of the calcu-
lation volume. To calculate the radial dose function, the absorbed dose along the x
axis (perpendicular the longitudinal axis of the source) is normalised to the absorbed
dose at a distance of 10 mm from the centre of the source along the x axis and divided
by the normalised (at r = 10 mm) geometry function, as shown in Equation 6 of the
AAPM TG43 U1 report [3]. To calculate the 2D anisotropy function, for a given radial
distance from the centre of the source (r) the absorbed dose is plotted as a function
of the angle from the longitudinal axis (θ), normalised to θ = 90°and then divided by
the normalised (again at θ = 90°) geometry function, as shown in Equation 8 of the
AAPM TG43 U1 report [3].
6.3 Results
6.3.1 Radial Dose Function
The radial dose function calculated in this study compared to Granero et al. [4] and
Taylor & Rogers [5] is shown in Figure 6.3. An active length of GL(r,θ) = 3.5 mm
was used to calculate the radial dose function from the calculated dose. Agreement
to within 1% for radial distances up to 15 cm was found when compared to both
studies. The increased discrepancy in the radial dose function at larger distances (r
>15 cm) may be due to the different size of water phantom used in the simulation. For
example, an 80 cm square cube was used in this study and in the study by Taylor &
Rogers [5], whereas an 80 cm diameter sphere was used in Granero et al. [4]. However,
Prez-Calatayud, et al. [112] have previously shown that for Ir-192 source a spherical
phantom of 40 cm radius effectively acts as an unbound phantom for distances up
to 20 cm from the source. Therefore, the increased statistical uncertainty at larger
distances due to the decrease in magnitude of the dose scored in these voxels may also
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be contributing to the larger discrepancy.
Figure 6.3: Comparison of calculated radial dose function with studies by Granero [4]
and Taylor & Rogers [5].
6.3.2 2D Anisotropy
The calculated anisotropy function, using an active length of GL(r,θ) = 3.5 mm, is
shown for a distance of 1 cm and 10 cm, in Figure 6.4a and Figure 6.4b, respectively. As
shown in both figures, the calculated anisotropy data agrees with both benchmark cases
within the calculated expanded uncertainty. Larger discrepancies can be observed at
polar angles between 0°-15°and 165°-180°due to the minor variations in source capsule
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modelling between the studies. In this study, the non-cable end weld of the stainless
steel shell is modelled as a cylinder of length 0.65 mm and diameter 0.85 mm whereas
in the studies by Graneo et al. [4] and Taylor & Rogers [5] the end weld is modelled
as a 0.108 mm thick conical section with a half angle of 23.6°and the radius of the
face being 0.17 mm. This conical section was then attached to a 0.49 mm long solid
cylindrical section to complete the end weld. This minor difference in the end weld
modelling was not observed to have a significant effect on the calculated anisotropy.
There is also a substantial decrease in magnitude of the dose scored in these voxels
due to the significant attenuation through the end welds. This leads to an increased
statistical uncertainty and may also contribute to the larger discrepancies in calculated
anisotropy between the studies.
(a) (b)
Figure 6.4: a) Calculated 2D anisotropy function at a radial distance of 1 cm, and b)
at 10 cm. As compared with studies by Granero [4] and Taylor & Rogers [5].
6.4 Discussion
The calculated radial dose function from this study is shown to agree with both the
Granero [4] and Taylor & Rogers [5] benchmark datasets within the calculated un-
certainty in the radial distance range of 1 200 mm. The 2D anisotropy was also
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found to agree with the two benchmark datasets across most of the investigated range.
Table 6.1: Uncertainty analysis for MC TG43 simulations used in this study.
Type A Type B
Statistical variation in absorbed dose determination
from repeated MC simulation runs.
1%
Variations of the source geometry from one source to
another in manufacturing process [4].
0.5%
Uncertainty in cross section library data for Ir-192 [116]. 0.5%
Effect of volume averaging on absorbed dose calculation
in sensitive volumes [117].
0.1%
Combined TG-43 simulation uncertainty 1.2%
The uncertainties quoted in the results section have been evaluated using the com-
bination of both type A and type B uncertainties combined in quadrature (Table 6.1),
as recommended in TG43-U1 [3]. Type A, or statistical uncertainties are inherent to
the MC technique. In this study 109 primary photons are generated, resulting in a
statistical uncertainty in the absorbed dose of less than 1% (1σ). Type B uncertainties
arise in this study due to uncertainties in the cross section data and variations of the
source geometry from one source to another in manufacturing process [4]. Ballester
et al. [116] determined the uncertainty in the cross section library to be 0.5% and
Granero et al. [4] estimated the uncertainty arising due to variations in manufactur-
ing of the source to be less than 0.5%. Additionally, as mentioned previously, the
thickness and resolution of the voxels were chosen so as to ensure the effects of volume
averaging are less than 0.1%. This results in a combined type B uncertainty of 0.7%
and a corresponding total combined uncertainty in the absorbed dose as 1.2% (1σ).
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6.5 Conclusion
In this chapter the TG43 parameters for the Flexisource are calculated using the
Geant4 MC simulation toolkit. The results obtained for both the radial dose function
and 2D anisotropy agree with two benchmark datasets within the calculated expanded
uncertainty. Therefore, this model of the Flexitron Ir-192 HDR brachytherapy source
can be considered acceptable for use in further dosimetric studies. As mentioned
above, these dosimetric studies will be discussed in future chapters of this thesis,
including simulation of the response of the MP 2D diode array embedded into the
patient couch, in order to study the feasibility of using the MP for in-vivo source
tracking and identification of potential errors in HDR pBT treatments.
Chapter 7
HDR Prostate Brachytherapy
In-vivo Source Tracking using the
Magic Plate Diode Array: A Monte
Carlo Study
7.1 Introduction
This work in this chapter aims to investigate the feasibility of using the MP diode
array for in-vivo source tracking of a HDR pBT treatment. Previous studies performed
with the MP in homogeneous phantom media and have reported source localization
accuracy of less than 1 mm [47, 72, 39] and temporal resolution of 1 ms [72], making it
an ideal device for real-time source tracking. It is hypothesised that the introduction
of heterogeneous media associated with the patient geometry may compromise the
Part of this chapter has been published in the Journal of Applied Clinical Medical Physics: Poder,
J, Cutajar, D, Guatelli, S, Petasecca, M, Howie, A, Bucci, J & Rosenfeld, A 2018, HDR brachytherapy
in vivo source position verification using a 2D diode array: A Monte Carlo study, Journal of Applied
Clinical Medical Physics, vol. 19, no. 4, pp. 163-72.
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accuracy of source localization using this device.
To assess the feasibility of source localization using the MP in the presence of pa-
tient related heterogeneities, MC simulations were performed using the Geant4 toolkit
(v4.10.01) [86, 111]. During the HDR pBT treatment simulations, the Flexisource Ir-
192 source (Elekta Brachytherapy, Veenendaal, The Netherlands) was simulated inside
a voxelized patient geometry, and the dose deposited within the sensitive volume of
each detector in the couch embedded 11x11 diode array was evaluated. The simulated
detector dose was then used to determine the distance of all detectors in the array to
each of the simulated source positions. Finally, the source position was determined
using an iterative procedure where the source position is first estimated, and then
repeatedly refined based upon the agreement of the predicted geometric distance from
the source to the detectors against those determined by the detectors in the array.
7.2 Materials & Methods
7.2.1 Ir-192 Flexisource Model
The same geometrical Ir-192 Flexisource model as described in the Chapter 5 was used
in the simulations, along with the same gamma spectrum and interaction processes
previously described.
7.2.2 Magic Plate 121 Model
The MP121 is a 2D silicon diode array originally developed at the Centre for Medical
Radiation Physics (CMRP), University of Wollongong, Australia for the purpose of
IMRT QA [118]. The MP121 consists of an 11x11 array of epitaxial diodes mounted
on a 0.6 mm Kapton substrate using the drop-in technique. The epitaxial layer of the
MP121 diode is 50 µm thick p-Si grown on top of a 375 µm thick, low resistivity p+
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substrate. The sensitive volume of the individual element defined by the n+ region is
0.6 x 0.6 x 0.05 mm3, while the size of the die is 1.5 x 1.5 mm2, the detector pitch is
10 mm [118]. The drop in mounting of the epitaxial diode attempts to minimize the
energy dependence and improve the angular response of the diodes by avoiding the
use of high Z metal contacts above the sensitive area. This is accomplished instead by
using thin Aluminium contacts on the periphery of the 0.6 x 0.6 mm2 n+ ion implanted
regions, the lead of the diode is then fully embedded in the Kapton substrate and the
diodes face is aligned with the Kapton substrates front surface [118]. The MP121
geometry was created in the simulations used in this study based on the description
by Wong, et al. [118] and is shown in Figures 7.1a) and 7.1b). In the simulations,
the MP121 was embedded inside a 120 mm thick carbon couch, offset 5 mm from its
anterior surface.
(a) (b)
Figure 7.1: a) Schematic of the MP121 diode spacing, the origin of the coordinate
system is defined as the bottom left corner diode of the MP121. (b) Close up of the
diode design (distances in mm).
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7.2.3 Patient Geometry
The patient model was created by converting a DICOM CT studyset from a prostate
HDR brachytherapy treatment into a voxelized model that can be used in Geant4, as
shown in Figure 7.2. This was achieved by first converting the Hounsfield unit (HU)
numbers to a mass density value using a CT-density curve, and then converting from
mass density to a material using a look up table [119, 120, 121]. Once imported into
the simulation, a geometrical phantom is created, within which is an array of voxels
containing the materials (and their compositions) determined from the HU numbers
[121]. The compositions and the densities of materials used in the simulations were
obtained from the AAPM TG 186 Report [35]. The voxel size was set to 3x3x3 mm3 for
the patient geometry in this study. This voxel size was chosen to model an accurate
geometrical definition of patient related inhomogeneities and prevent prohibitively
long simulation times. It is acknowledged that this voxel size is larger than that used
clinically, but is less important in the context of this current study as dose deposition
is not of concern within the patient volume, only the transport of the radiation. To
prevent overlapping volumes, which causes tracking errors in simulations, a parallel
geometry was used to place the source within the patient geometrical phantom at the
planned dwell positions [122].
7.2.4 Dwell Positions and Dose Scoring
A selection of 12 source positions from a HDR pBT treatment plan created in the On-
centra BTPS (Elekta Brachytherapy, Veenendaal, The Netherlands) were used in the
simulations. The source position coordinates were selected as three consecutive source
positions from four catheters. The catheters were selected such that they spanned the
extent of the prostate (left-right and anterior-posterior), to determine if consecutive
source positions along a catheter could be localized by the MP at the maximum and
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Figure 7.2: Partial axial view of voxelized patient geometry in Geant4 source position
simulations. The carbon couch is shown below the patient geometry outlined in green,
the Kapton substrate in blue and the diode array in pink.
minimum distances expected in a clinical HDR pBT treatment. The step size of the
source used in the BTPS was 3 mm.
To calculate the absorbed dose in each of the sensitive silicon volumes, the total
energy deposited in each volume was obtained and divided by the total mass of the
volume. Each source position was simulated with 109 primary photons for each sim-
ulation run. A total of 20 simulation runs were performed for each source position;
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results from each run were averaged and the standard deviation (k=1) was less than
1%.
Each of the source localization simulations were then repeated with each voxel
in the patient geometry overridden to the density of water, to compare the source
localization accuracy of the MP with and without the presence of patient related
inhomogeneities.
7.2.5 Source Tracking Algorithm
To determine the distance of each of the 12 source positions to all detectors in the
array (αi), a separate group of simulations were first performed to determine the dose
deposited in a single detector placed at 10 mm from the source (D10), along the z axis
(perpendicular to the longitudinal axis of the source) in a water phantom. A total of
10 simulations of 109 primary photons were performed for this configuration, and the
dose deposited in the single detector averaged across the 10 simulations. This average
dose was then used to normalize the dose from each detector in the patient geometry
simulations (Di), before converting the relative dose to radial distance. No corrections
are required for the response of the MP121 (and therefore the dose calculated) at the
distances from the source considered in these simulations, as shown by Espinoza et.
al. [74].
αi = Di/D10. (7.1)
The radial distance from each detector to each source position can then be determined
by converting the relative diode dose to distance via a fit of the TG43 parameters
calculated in Chapter 6. Based on the derived distances (ri) of each diode (i) in
the array to the source, the estimated source position, Ses(a,b,c) can be calculated.
The geometrical distance, di, between Ses and the coordinate of the i-th detector
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Di(xi, yi, zi) is calculated by
di(a, b, c) =
√
(a− xi)2 + (b− xi)2 + (c− zi)2 (7.2)
To determine the true source position, the geometrical distance, di, is fitted to the
derived distance, ri, by adjusting the estimated source position, employing a non-
linear least squares fit method to determine the estimated source position. In least
squares fitting, the estimate of error assessment can be expressed as the sum of squares
of the relative error, χ2









and assumes that the derived distance, ri, is correct. As there is an uncertainty
associated with deriving ri, if the estimated source position were equal to the true
source position, then calculating the square of the sums of the percentage difference
of the value di and ri would result in a minimum value.
To determine a source position that gives the minimal value to the estimate χ2 a
multi-variable Newtowns method approach is adopted. Newtons method is used in this
case to determine the roots of a function by finding successively better approximations.
In this analysis, it is necessary to determine the minimum values of χ2 for all three










Newtons method for the three source coordinates can be expressed for the k-th iteration
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as
ak = ak−1 − δak−1
bk = bk−1 − δbk−1
ck = ck−1 − δck−1
(7.5)
where δa, δb and δc are the changes made to the source position to produce the
improved approximation. These changes can be determined by solving a set of linear


































This process is repeated until all δs are sufficiently small, or until further estima-
tions of the source coordinates fail to reduce χ2. This approach can converge rapidly
to a minimum when close, as all three source coordinates are modified in a single
iteration. The initial guess is determined by the coordinates of the detector with the
highest response, Dmax(xmax, ymax, z = 0), as the source is assumed to be closest to
this position. The sum of the squares is calculated using the first estimation of the
source position,
S0es = (a
0, b0, c0) = Ses(xmax, ymax, rmax) (7.7)
This approach assumes that the diodes are present within a homogeneous water
phantom, when in fact the diode dose was calculated within the heterogeneous patient
voxelized phantom. Once an initial estimation of the source position is found, a
correction factor is then applied to the response of each of the MP detectors to take
into account the angular dependence of the detectors. The source position is then
re-estimated using the above method but uses the initial estimated source position of
the previous calculation. Finally, the calculated source position is compared to known
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source positions obtained from the Oncentra BTPS.
7.3 Results
The average difference between MP predicted and actual source positions was found to
be 2.1 ± 0.8 mm (k = 1) when all detectors in the array were used in the localization
algorithm. Table 7.1 summarizes the localization results in three dimensions, along
with the calculated 3D difference vector, for different number of detectors used in the
source localization algorithm. When not all detectors in the array were used in the
source trackng algorithm, the detectors with the highest deposited dose were chosen.




9 25 49 81 121
X 0.5±1.0 0.2±0.4 0.0±0.2 0.0±0.2 0.2±0.2
Y 0.5±1.1 0.0±0.5 0.0±0.3 0.2±0.3 0.5±0.5
Z 1.8±0.5 1.8±0.5 1.9±0.5 2.0±0.5 2.0±0.5
3D 2.4±1.0 1.9±0.5 1.9±0.5 2.0±0.5 2.1±0.6
As can be seen from Table 7.1, the MP could localize the source to within 1 mm in
the X & Y directions (left/right and superior/inferior directions, respectively). How-
ever, it consistently overestimated the distance in the Z direction (anterior/posterior
direction), with an average error of 1.9 mm.
The source tracking simulations were then repeated using the exact same methods,
but with each voxel in the patient geometry assigned a density of water (Figure 7.3).
The heterogeneous and water only results were compared by means of a students t
test (p <0.05) in each of the X, Y and Z directions. Only the Z direction differences
7.4. Discussion 92
were found to be statistically significant (p <0.001)
The heterogeneous results were used for a one-way ANOVA [123] analysis (p <0.05)
to determine if there was a statistically significant difference in the localization accu-
racy depending on the number of detectors used. The only significant difference was
found for the 3D vector (p <0.001). Subsequent Students t tests were performed to
compare the datasets for the 3D vector. From this, it was found that only the dataset
with 9 detectors had statistically significant differences to the other groups.
7.4 Discussion
The uncertainties quoted in this study have been evaluated using the combination of
both type A and type B uncertainties combined in quadrature, as recommended in
AAPM TG43-U1 [3] and AAPM TG138 [30]. A summary of the uncertainty budget for
the source tracking simulations is presented in Table 7.2. Note that the uncertainties
related to the response of the MP121 and its associated correction factors are not in-
cluded in this table.
Table 7.2: Uncertainty analysis for source tracking MC simulations used in this study.
Type A Type B
Statistical variation in absorbed dose determination
from repeated MC simulation runs.
1%
Variations of the source geometry from one source to
another in manufacturing process [4].
0.5%
Uncertainty in cross section library data for Ir-192 [116]. 0.5%
Effect of volume averaging on absorbed dose calculation
in sensitive volumes [117].
0.1%
Uncertainty in composition of tissues used during source
tracking simulations[124].
2%




Figure 7.3: a) Difference between MP predicted and actual source position for het-
erogeneous and water only simulations in X direction, b) Difference in Y direction, c)
Difference in Z direction, d) 3D difference vector. Coordinate system orientation is
shown in Figures 6.1 & 6.1.
7.4. Discussion 94
In a water only geometry, the MP121 was able to localize the source to within 1 mm.
The source lozalization accuracy however was found to decrease with the introduction
of inhomogeneities. This decrease in accuracy of source position localization due to the
presence of inhomogeneities was found to be primarily in the direction perpendicular
to the diode array (Z direction). This is due to the source localization algorithm
[125, 74] Z direction estimate being more sensitive to the changing ratio of primary
to secondary photons due to the presence of inhomogeneities and increased source to
detector distance.
The distance estimate in the Z direction is depends directly on the absolute dose
deposited in the detector array, whereas source localization in the X and Y directions
depends only on the relative difference between the distance estimate for each detector
and therefore is less sensitive to inhomogeneities. Small inhomogeneities however can
affect the X and Y estimate if a smaller number of detectors are used in the localization
algorithm [125, 74].
This indicates that to track the Ir-192 source with the desired accuracy during
HDR pBT treatments a correction may be required, based on density information
obtained from the patient CT scan performed prior to treatment. This information
could be used, along with a MBDCA [35] built into the localization algorithm to more
accurately predict the source to detector distances.
Moreover, it was found that source localization accuracy can be improved with
an increased number of detectors used in the localization algorithm. By increasing
the number of detectors used in the localization algorithm, a redundancy is built in
to reduce the uncertainty introduced due to small heterogeneous media in the patient
geometry [76]. The increased number of detectors is also beneficial due to the relatively
isotropic dose profile at large source to detector distances [74].
Previous studies have shown that source tracking using EPIDs is achievable. How-
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ever, these studies have also shown that source tracking using EPIDs is restricted by
the limited frame rate and read-out electronics of the devices and can result in a sig-
nificant number of dwell positions not being captured by the EPID when performing
source tracking [126]. Source trackng using EPIDs also requires large and expen-
sive systems that have limited availability. This study has shown that similar source
tracking accuracy to EPIDs [126, 71, 70] may be achieved with the MP system. Fur-
thermore, the MP system has been shown to have a superior timing resolution of less
than 1 ms [72]. As such, the MP delivers a dedicated, inexpensive HDR brachytherapy
in-vivo source tracking system with superior timing resolution that can easily be mass
produced and is practical for routine clinical use.
The results of this study, along with previously published experimental results [47,
74], indicate that the MP will have sufficient sensitivity to detect errors in the order of
1-2 mm during the delivery of HDR pBT treatments when embedded in a carbon fibre
couch beneath the patient. Such errors may be due to incorrect catheter connection or
catheter reconstruction error. In Chapter 5 it was found that in-vivo source tracking
error thresholds to prevent clinically significant changes in dose distributions were
directionally dependent, as well as dependent on the end-point. In the cranio-caudal
direction a 2-3 mm error threshold was found to be appropriate. In this Chapter
the MP121 was able to track the source to within 0.5 mm in this direction. In the
medial-lateral direction, a 1-2 mm error threshold should be applied according to the
results in Chapter 5. Again, from the results in this chapter the MP121 could track the
source to within 0.5 mm in this direction. However, for the anterior-posterior direction
in Chapter 5, a 1-2 mm error threshold was deemed to be appropriate to prevent
clinically significant changes in delivered dose distributions. But, in this chapter the
MP121 was able to track the source to within 2 mm (assuming perfect co-registration
of the MP121 to the BTPS coordinate system and negligible corrections required for
7.5. Conclusion 96
the MP121 response). Therefore in the case of the anterior-posterior direction, the
error appropriate threshold is approximately equal to the accuracy of source tracking
using this device, which may result in a suboptimal sensitivity and/or specificity when
performing source tracking of these TRUS based HDR pBT treatments using the
MP121.
7.5 Conclusion
Source localization using the MP121 during a HDR pBT treatment was examined
using MC simulations. In a homogeneous geometry, the MP121 was able to localize the
source to within 1 mm. The effect of tissue inhomogeneities in the patient geometry on
source localization accuracy was also examined and was found to increase the difference
between MP121 predicted and known source positions from the BTPS to 2.1 ± 0.81
mm (k = 1). However, this accuracy can be improved using density information
obtained from CT with the MP accurately registered to the patient geometry, making
the proposed tool attractive for use as a real time in-vivo source tracking device in
HDR brachytherapy for prostate cancer. With the global trend being towards real-
time pBT treatment planning based on TRUS imaging, future chapters will aim to
examine the effect of the TRUS probe on source localization accuracy.
Chapter 8
Feasibility of Real-time In-vivo




This chapter presents the study performed to examine the feasibility of performing
real-time in-vivo source tracking during TRUS based HDR pBT treatments.
HDR pBT treatment plans are traditionally performed with the use of a post-
operative CT scan. The major drawback of this technique is that it necessitates
movement of the patient off the operating table and out of the dorsal lithotomy po-
sition. Multiple studies have reported that movement of the patient in this manner
Part of this chapter has been published in the Physica Medica journal: Poder, J, Cutajar, D,
Guatelli, S, Petasecca, M, Howie, A, Bucci, J, Carrara, M & Rosenfeld, A 2019, A Monte Carlo study
on the feasibility of real-time in vivo source tracking during TRUS based HDR pBT treatments,
Physica Medica, vol. 59, pp. 30-6.
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may increase the risk of catheter displacement in the inferior direction, relative to the
prostate, in the time between CT scanning and treatment [127, 107]. The use of TRUS
for treatment planning [128] has been shown to reduce the magnitude of these shifts,
as well as improve visibility of the prostate and OARs [128] Modern BTPS are able to
use the US echoes of the implanted catheters for the definition of the catheter position
within the patient, allowing for real-time HDR pBT treatment planning [128]. Correct
identification of catheter positions on these images however can be difficult, and there
remains a need for comprehensive pre-treatment and/or in-vivo QA [104, 56, 55].
The aim of this study is therefore to determine the feasibility of using a 2D diode
array for in-vivo source tracking during TRUS based HDR pBT using Monte Carlo
simulations in the Geant4 toolkit (v4.10.01) [86, 111]. The presence of the TRUS
probe was simulated inside the patient to evaluate its effect to the source position
detection, and methods are evaluated for overcoming the presence of the probe.
8.2 Materials & Methods
8.2.1 Ir-192 Flexisource Model
The same geometrical Ir-192 Flexisource model as described in the Chapter 6 was used
in the simulations, along with the same gamma spectrum and interaction processes
previously described.
8.2.2 Magic Plate 900 Model
The Magic Plate 900 (MP900) contains diodes mounted on a 0.6 mm Kapton substrate
using the edgeless-drop-in technique (Figure 8.1), as described in a study by Petasecca
et al. [129]. These diodes have an improved angular dependence (less than 2%)
compared to those used in the previous design of this system, thereby simplifying the
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source reconstruction algorithm and improving source tracking accuracy. Furthermore,
the diodes have a larger sensitive volume (higher sensitivity) to allow for enhanced
signal to noise ratio at larger source-to-detector distance. The diodes are arranged in
the Kapton carrier with a 7 mm pitch, resulting in a total array size of 21 cm x 21 cm.
The materials and geometry of the MP900 were constructed within the simulations
according to the description of the device above, embedded inside a 120 mm thick
carbon fibre couch, offset 5 mm from its anterior surface.
Figure 8.1: Schematic of the MP900 and of the edgeless diode design used source
tracking simulations. All dimensions are in millimetres, image is not to scale.
8.2.3 Patient Geometry
The model of the patient anatomy in the simulations was created by converting three
DICOM CT studysets from HDR pBT treatments. As in Chapter 7, this was accom-
plished by initially converting the Hounsfield unit (HU) to a mass density values using
a CT-density curve, and then converting from mass density to a material using a look
up table [119, 120, 121]. The patient geometry in Geant4 is then created as a geo-
metrical phantom consisting of an array of voxels containing the materials (and their
compositions) determined from the HU [121]. The compositions and the densities of
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materials used in the simulations were obtained from the AAPM TG 186 Report [35].
The voxel size was set to 3x3x3 mm in this study.
8.2.4 Trans-rectal Ultrasound Probe Model
A TRUS probe was modelled inside the rectum of the voxelized patient geometries by
utilizing a parallel geometry [122] to prevent overlapping volumes in the simulation,
e.g. patient rectum and TRUS probe. These overlapping volumes cause errors in the
tracking geometry of Geant4 simulations, leading to erroneous results. The TRUS
probe was constructed based on the Endocavity Biplane Transducer Type 8848 pro-
duced by BK Medical. The model of the probe consisted of a 110x15x3 mm bar of
brass (70% Copper, 30% Zinc, effective atomic number of 29.5), embedded inside a
cylindrical Silicon casing (length 200 mm, diameter 22 mm).
It should be noted that this model may not be representative of the true construc-
tion of the model 8848 probe, as details of the internal construction of the probe were
unable to be obtained from the manufacturer. Therefore, a model was used that was
intended to match the internal construction of the probe to the best of our knowledge
and mimicked the construction of a probe analogue previously used in experiments by
our institution [74]. Due to the presence of the high atomic number materials inside
the TRUS probe, it was expected that the TRUS probe would attenuate the signal
collected by the MP900 significantly, negatively affecting the source tracking accuracy.
Nevertheless, its important to note that the TRUS probe must remain in the rectum
during patient irradiation in order to not modify the patients anatomy acquired for
treatment planning [56].
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8.2.5 Dwell Positions and Dose Scoring
Three complete HDR pBT treatments were simulated, consisting of three unique vox-
elized patient geometries. The source position locations from the treatment plans were
re-created in the simulation geometry by using the 3D source position locations ob-
tained from the DICOM RTPlan files in the BTPS. As the patient geometry is also
re-created in the simulations directly from the DICOM files, the position of the dwell
locations relative to the patient anatomy in the simulations matches the BTPS. The
characteristics of the three HDR pBT plans included in the study are outlined in Table
8.1. The Flexisource model used in the simulations is described in Chapter 6.
Table 8.1: Characteristics of the three HDR pBT plans considered in the study.
Number of Catheters Number of Source Positions
Patient 1 19 154
Patient 2 22 165
Patient 3 18 153
The total energy deposited in the sensitive volume of each diode in the array was
tallied during each simulation, which consisted of a total of 109 primary photons. The
total energy deposited in the sensitive region of each diode was then divided by the
mass of the sensitive volume to calculate the dose deposited. The source positions
were then determined using the average diode dose as input into an source tracking
algorithm [99, 72, 125].
Finally, the MP900 determined source positions were compared to known source
positions input into the simulations, which were obtained from the Oncentra Prostate
(v4.2.3 Elekta Brachytherapy, Veenendaal, The Netherlands) BTPS. Source positions
obtained from the BTPS coordinate system were converted to that of the MP900
coordinate system, as the position of the MP900 relative to the patient geometry is
a known, fixed distance (the MP900 is rigidly embedded into the carbon fibre couch
below the patient) within the simulation geometry. The simulations were repeated
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with the TRUS probe replaced by tissue equivalent material in the patient geometry
to examine the effect of the TRUS probe on the source tracking accuracy.
8.2.6 Source Tracking Algorithm
The same source tracking algorithm as Described in Chapter 7 was utilised in this
study with some modifications. Firstly, the algorithm was adapted to be used with
the new version of the MP900 array with the increased number of detectors. Secondly,
the correction factor for the angular dependence of the diodes was removed.
Lastly, to determine if the same accuracy of source tracking can be achieved both
with and without the TRUS probe present, a thresholding technique was applied to
the source tracking algorithm. Using the data from the simulations with the TRUS
probe present, the maximum dose deposited in any single diode was found for each
source position. Then, for each source position in the three patient plans a threshold
was applied, ranging from 50% - 90% of the maximum dose deposited in the array in
10% increments. Any diode with dose deposited below this threshold is ignored in the
algorithm, and the optimal threshold level found that gave the best results as input
into the source tracking algorithm when all source positions from the three treatment
plans were considered.
The average and maximum differences between MP900 predicted and actual source
positions obtained with the TRUS probe, without the TRUS probe, and TRUS probe
corrected (i.e. applying the optimal threshold), were computed and compared across
all three patient volumes. Results without the TRUS probe and TRUS probe corrected
were also compared by means of a Wilcoxian matched pair test. A p-value of <0.05
was considered significant. The test was performed using the R software (v3.5.1, The
R Foundation for Statistical Computing, Vienna, Austria).
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8.3 Results
The average 3D error vector of source tracking in the presence of the TRUS probe is
shown in Table 8.2 for each direction within the three patient volumes, including: the
patient left-right direction (X), superior-inferior direction (Y), and anterior-posterior
direction (Z). The average 3D error vector for all source positions in the three treatment
plans was found to be 11.9 ± 2.4 mm (k = 1). Figure 8.2a presents the distance
calculation between each diode in the MP900 array from a source position in patient 1s
plan with the TRUS probe present. The colour scale represents the MP900 calculated
distance (in mm) from each diode to the source. The effect of the TRUS probe can
clearly be seen in the figure, resulting in an incorrect distance calculation for the diodes
shadowed by the probe.
The simulations were then repeated without the TRUS probe present in the patient
geometry examine the effect of the TRUS probe on the source tracking accuracy.
Figure 8.2b presents the distance calculation between each diode in the MP900 array
from a source position in patient 1s plan without the TRUS probe present. The average
3D error vector for all source positions in the three treatment plans without the TRUS




Figure 8.2: a) Distance calculation (mm) between the source and each diode in the
MP900 from a source position in Patient 1 plan, affected by the presence of the TRUS
probe. b) Distance calculation, without the TRUS probe present, c) Distance calcu-
lation with 70% threshold applied, and diodes with red colours not included in the
reconstruction algorithm.
A thresholding technique was applied to the verification algorithm with the TRUS
probe present. Figure 8.2c presents the distance calculation between each diode in
the MP900 array from a source position in patient 1s plan with the TRUS probe
present and a 70% threshold applied. As can be seen from the figure, the threshold is
able to eliminate the diodes shadowed by the TRUS probe as input into the tracking
algorithm. The effect of the application of different threshold levels in the source
tracking algorithm is shown in Figure 8.3. The optimal threshold level, averaged over
all source positions in the three treatment plans was found to be 70%. By disregarding
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the signal of all diodes below 70% of the maximum signal of any diode in the array,
an average source tracking accuracy of 1.8 ± 0.4 mm (k = 1) can be achieved in the
clinically relevant condition of the presence of the TRUS probe inside the rectum.
Figure 8.3: Effect of threshold level in the source tracking algorithm. The 3D error
vector in the presence of the TRUS probe is shown in green (k=1). The 3D error
vector without the TRUS probe is shown in red (k=1). The 3D error vector with
different threshold levels applied is shown in blue, pink, and orange, for patients 1, 2
and 3, respectively (k=1).
As can be seen in Table 8.2, the variation in the 3D source tracking accuracy
across the three patient volumes is less than 0.5 mm. This result highlights the ex-
cellent reproducibility of the MP900 system and associated source tracking algorithm,
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Table 8.2: Average difference between MP900 predicted and actual source positions in
mm, without and with a TRUS probe (corrected with 70% threshold) with standard
deviation (k=1) in the patients rectum.















X 0.4±0.4 0.6±0.5 0.4±0.4 0.7±0.6 0.5±0.4 0.7±0.8
Y 0.4±0.2 0.6±0.5 0.4±0.2 0.6±0.4 0.5±0.3 0.7±0.7
Z 1.3±0.2 1.6±0.4 1.3±0.2 1.4±0.4 1.5±0.5 1.5±0.8
3D 1.4±0.3 1.8±0.6 1.4±0.3 1.7±0.6 1.7±0.4 1.8±0.7
regardless of variations in patient related tissue inhomogeneities. The maximum differ-
ence between MP900 predicted and actual source position was 15.4 mm, 2.2 mm, and
3.0 mm, with the TRUS probe, without the TRUS probe, and TRUS probe corrected
(70% threshold), respectively across all three patient volumes. The difference between
the latter two datasets was found to be statistically significant, with p <0.001.
The results were broken down further to show the average 3D error achieved per
catheter (Figure 8.4) for patient 1 only, both without the TRUS probe and with
the 70% threshold level applied. The catheter numbers increase in the posterior to
anterior direction; therefore, the increasing catheter number represents an increasing
distance between the source and the MP900 array. Typical average distances between
the source positions in each catheter and the MP900 array ranged from 95 mm to
145 mm. A trend is observed showing an increased 3D error with increasing average
distance between the source and the array.
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Figure 8.4: Average 3D source tracking error in each catheter considered in the study
for patient 1, 1 standard deviation. Red columns show the average error without the
TRUS probe. Blue columns show the average error with the TRUS probe present and
a 70% threshold level applied.
Figure 8.5 presents a box-whisker plot focusing on catheter 2 and catheter 8 from
the patient 1 plan. Catheter 2 is an example of a catheter which is not shadowed by
the TRUS probe as viewed from the MP900 array. Catheter 8 is an example where
the TRUS probe shadows the primary radiation from the Ir-192 source from most
detectors in the MP900 array.
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Figure 8.5: 3D source tracking error in the form of a box-whisker plot for catheter 2
(C2) and catheter 8 (C8). TRUS probe present and TRUS probe corrected results are
presented for each catheter.
8.4 Discussion
The uncertainties quoted in this study have been evaluated using the combination of
both type A and type B uncertainties combined in quadrature, as recommended in
AAPM TG43-U1 [3] and AAPM TG138 [30]. A summary of the uncertainty budget
for the source tracking simulations is the same as presented in Chapter 7.
The presence of the TRUS probe was found to significantly affect the accuracy of
source tracking in all three dimensions. Source tracking accuracy without the TRUS
probe using the MP900 was found to be similar, but improved by approximately 0.5
mm, to that found previously using the MP121 device in Chapter 7. The major
8.4. Discussion 109
discrepancy remains in the z direction (patient anterior-posterior direction). The dis-
crepancy in the z direction has been shown in Chapter 7 to be due to the non-water
equivalence of patient tissue related inhomogeneities between the source and the diode
array. This was shown by repeating the simulations with each voxel in the geometry
assigned a density of water, resulting in a significant improvement in source tracking
accuracy. This effect is highlighted even more so in Figure 6.4, where an increased
3D error vector is observed with increasing distance between source position and the
array, due to the increasing likelihood of the material composition between the source
and the array being different to that of water.
The effect of the TRUS probe on source tracking accuracy can be overcome using
a thresholding technique. An optimal threshold level of 70% of the maximum diode
signal was found for all source positions in three complete HDR pBT treatment plans.
With this threshold of 70%, approximately 60% of the detectors in the MP900 are not
being used for source position verification for the reported example case (patient 1).
However, the total number of detectors used in the verification algorithm under these
conditions is on average equal to 315. This is approximately 2.5 times the total number
of detectors in the previous version of the device (MP121 array) and justifies the need
for the MP900 for this purpose. As shown in Figure 8.3, the 70% threshold level
was found to be optimal for all three patient geometries, and there was remarkably
little variation in source tracking accuracy between the three patient geometries. The
optimal threshold level may depend more on the TRUS probe design and composition,
rather than the patient geometry. The effect of the TRUS probe type and design on
the optimal threshold level will be investigated further in future experimental studies
with the MP900.
Figure 8.5 shows on patient 1 an example of a catheter (catheter 2) which is not
shadowed by the TRUS probe as viewed from the MP900 array and of a catheter
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(catheter 8) where the TRUS probe shadows the primary radiation from the Ir-192
source from most detectors in the MP900 array. Even for catheter 8, which is posi-
tioned directly anterior to the TRUS probe, the modified source tracking algorithm re-
sults in a similar source tracking accuracy to when no probe is present. However, when
compared to catheter 2, the modified source tracking algorithm applied to catheter 8
results in larger discrepancies relative to when there is no probe present. As shown in
Table 8.2, there is a higher standard deviation of the 3D error results in the TRUS
probe corrected group (0.6 mm) compared to the results without the TRUS probe (0.3
mm). This is due to the larger uncertainty in correcting for the presence of the TRUS
probe for catheters that are located directly above the probe where less detectors in
the MP900 array can be used for input into the verification algorithm. In general,
3D errors resulted significantly higher (p <0.001) in the TRUS probe corrected group
than in the group without TRUS probe. Nevertheless, an average source tracking ac-
curacy lower than 2 mm (i.e., 1.8 ± 0.4 mm) can be achieved in the clinically relevant
condition of the presence of the TRUS probe inside the rectum, after application of
the TRUS probe correction method.
Source position detection is in principle impossible, even applying a threshold tech-
nique, if the source is so close to the probe that its primary radiation oriented towards
the array is shielded by the probe. Defining a the distance between the centre of the
TRUS probe and the array, b the distance between the upper surface of the TRUS
probe and the source, h the length of the array (i.e. 100 mm for the MP121 and 210
mm for the MP900) and d the diameter of the probe (i.e. 22 mm for the Endocavity
Biplane Transducer Type 8848 produced by BK Medical) (Figure 8.6a), the following
equation (a+b+d/2)/h=(b+d/2)/d is valid when the shadow of the source matches
the lateral edges of the array. In Figure 8.6b, this equation was used to simulate b
depending on both a and the diode array dimensions. According to the plot, the use
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of MP900 allows the reconstruction of the source position even if it is over the TRUS
probe and close to it, covering all the possible clinical situations. This wouldnt be
possible with the MP121, in particular at increasing distances between TRUS probe
and detector array. A typical clinical example is shown in Figure 8.6c, with a needle
10.4 mm over the TRUS surface.
(a) (b)
(c)
Figure 8.6: a) Schematic of the setup with the source, TRUS probe and MP900 array.
a is the distance between the centre of the TRUS probe and the array; b is the distance
between the external surface of the TRUS probe and the source; h is the length of the
array; d is the diameter of the probe. Image is not to scale, b) Minimum source-probe
distance b necessary to avoid the complete shielding of the primary radiation of the
source that would be detected by the array, plotted at changing array-probe distance
a, c) TRUS image of the prostate after needle implantation. The closest needle is 10.4
mm over the TRUS probe.
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The results from this study indicate that the MP900 will have sufficient sensitivity
to detect errors of approximately 2 mm in the delivery of TRUS based HDR pBT
treatments. Such errors may include incorrect catheter connection, incorrect source
strength, or incorrect reference length entered into the BTPS. Errors of this magnitude
may also be due to uncertainties in reconstruction of catheters on US images, for
example Rylander et al. [104] have shown that errors in catheter reconstruction on
TRUS images relative to MRI may be up to 9.6 mm. Furthermore, possible needle
displacements occurring during the treatment planning phase (i.e., post-imaging intra-
fraction modifications), which might result in changes in the dosimetry of the prostate
and OARs [56, 109], could also be detected by the use of MP900. Similarly to the
results discussed in Chapter 7, the results in this chapter show that the MP121 has
a source tracking accuracy of approximately 0.5 mm in the cranio-caudal and medial-
lateral directions, this is smaller than the derived error thresholds in these directions
found in Chapter 5 (2-3 mm, and 1-2 mm, respectively). Again, similarly to the
MP121 in Chapter 7, the source tracking accuracy of the MP900 in the anterior-
posterior directions was 2 mm, which is approximately equal to the derived error
threshold of 1-2 mm. These results indicate that the MP900 should have significant
sensitivity to detect clinically relevant source positioning errors in the superior/inferior
and medial/lateral directions, however clinically relevant source positioning errors in
the anterior/posterior direction may not be captured by the MP900.
There still remains, however, a number of significant challenges that must be over-
come before translating these source tracking simulation studies to routine in-vivo
source tracking in clinical practice. One example is the registration of the MP900 to
the BTPS coordinate system. The accuracy of source tracking can only be as good as
the registration between these coordinate systems, and any error in this registration
carries through as a systematic error in the comparison between planned and measured
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dwell positions. This may potentially result in an additional 1-2 mm of systematic er-
ror in the source tracking process, leading to a decrease in sensitivity/specificity when
using the device. Previous publications have incorporated stereoscopic imaging [101],
or EMT [83] in attempts to perform this registration. This issue remains one of the
most significant challenges for accurate localisation of the source position and will
also be a focus in future experimental studies using the MP900 system in combination
EMT systems with gel phantoms.
Another challenge that still must be overcome is the poor signal to noise ratio
experienced by the detector system at such large source to detector distances, when
the detector system is placed beneath the patient during HDR pBT. This poor signal
to noise ratio necessitates the use of longer integration times in the detector system and
may therefore preclude the system from performing real-time source tracking analysis.
This issue has been discussed in previous publications on the use of EPID devices for
source tracking [68, 71, 69, 126, 70]. The MP system, however, is capable of operating
with variable integration times between 14 to 9900 µs, with a stable sampling frequency
between 0.1 to 10 kHz. Previous publications on the application of the MP system
to HDR brachytherapy source tracking have demonstrated that real-time analysis is
possible [47, 72]. Optimisation of detector integration times and sampling frequencies
when performing source tracking in-vivo will be a focus of future studies.
Future studies will investigate the challenges of registering the MP900 to the BTPS
coordinate system, as well as optimisation of the MP900 readout and electronics for
in-vivo source tracking at large source to detector distances. It is acknowledged that
through this investigation that it will be demonstrated that the sensitivity of the
MP900 in detecting source positioning errors will be larger than the 2 mm value found
in this study through the Monte Carlo simulations. This will be validated further




This chapter presents a novel methodology for performing source tracking during real-
time TRUS based HDR pBT. Inclusion of the TRUS probe inside the patient was
shown to negatively affect source tracking accuracy. However, modification of the
source tracking algorithm using thresholding techniques was shown to improve source
tracking in the presence of the TRUS probe. An optimal threshold level of 70% of the
maximum diode signal at each source position was determined for all source positions
in three complete HDR pBT treatment plans, with minor variation observed across
the three patient volumes. Using this thresholding technique, similar accuracy can
be achieved as to when the TRUS probe is not present inside the patient volume,
highlighting the robustness of the proposed solution.
Chapter 9
Towards Real Time In-vivo Rectal
Dosimetry During Trans-rectal




Previous chapters of this thesis have focused on examining the feasibility of in-vivo
source tracking to detect clinically relevant source positioning errors during TRUS
based real-time HDR pBT. As discussed in Chapter 2, an alternative means of per-
forming IVTV during TRUS based HDR pBT is IVD. In-vivo dosimetry may provide
independent verification of dose delivered to OARs, as well as verification of treatment
delivery accuracy.
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Performing accurate and precise IVD in brachytherapy is extremely difficult due
to the challenges of precise detector positioning and the high dose gradient fields
associated with HDR pBT treatments. Carrara et al. have demonstrated an improved
measurement uncertainty using MOSkin dosimeters (Centre for Medical Radiation
Physics, University of Wollongong, Australia) through coupling of the dosimeters to
the TRUS probe during HDR pBT [56, 57]. By coupling the MOSkin dosimeters to
the TRUS probe, the uncertainty of relating the position of the dosimeters relative
to the source was reduced significantly. Consequently, in-vivo measurements over 18
treatment fractions yielded an agreement with treatment planning predicted doses to
within 3.6% ± 1.9% [57]. This system was labelled as the dual purpose probe (DPP),
a device which is suitable for both imaging and IVD during TRUS based HDR pBT.
The first aim of the work presented in this chapter was to reinforce the findings
presented by Carrara et al. at a second institution with a unique clinical workflow. The
second aim was to examine the feasibility of performing catheter-by-catheter analysis
of in-vivo rectal dosimetry during TRUS based HDR pBT. The catheter-by-catheter
analysis will be performed with the aim to verify the dose delivered to the rectum in
real-time as well as to verify the accuracy of treatment delivery.
9.2 Materials & Methods
9.2.1 Treatment Technique & Patient Characteristics
Thirteen patients treated with a HDR pBT boost in the period of 2017-2019, were
enrolled in this study. The HDR pBT boost was delivered as 2 fractions of 9 Gy
delivered 1 week apart, with the aim to deliver 18 Gy to the target volume using
an Ir-192 source. The HDR pBT boost was delivered prior to the EBRT component
of the treatment, which aimed to whole pelvis with a prescription of 46 Gy in 23
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fractions. Seven patients received in-vivo rectal dose monitoring for both fractions of
their treatment, whilst 6 patients received in-vivo rectal dose monitoring for only 1 of
their 2 boost fractions. Therefore, a total of 20 treatment fractions were included for
analysis in this study. All patients included in the study were treated using the TRUS
based real-time HDR pBT technique as described in Chapter 4.
9.2.2 MOSkin Dosimeters and Calibration Technique
MOSkin dosimeters are uniquely designed MOSFET dosimeters developed at the Cen-
tre for Medical Radiation Physics, University of Wollongong, Australia. The MOSkin
design utilises a thin layer above the sensor, that replaces the dome style epoxy resin
used for build-up on traditional MOSFET dosimeters used for IVD [130]. This unique
design allows for a water equivalent measurement depth of 0.07 mm from the surface
of the dosimeter. Furthermore, the MOSkins are produced through a patented drop-in
techniques that allows the MOSFET die to be embedded in a Kapton carrier and to
provide an electrical connection without the presence of high Z materials. This, along
with the small sensitive volume (4.8 x 10-6 mm3), makes the MOSkin an ideal dosime-
ter for brachytherapy IVD where dose distributions are characterised by steep dose
gradients and relatively low energies. Additionally, the physical size of the MOSkin
(0.45 mm thick x 1.8 mm wide x 330 mm length), as shown in Figures 9.1 and 9.2
allows for placement of the dosimeter onto the TRUS probe during TRUS based HDR
pBT without perturbing the geometry of the patient or the dose distribution.
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Figure 9.1: Top view schematic of the MOSkin dosimeter.
Figure 9.2: Side view schematic of the MOSkin dosimeter.
The MOSkin dosimeters used in this study were calibrated using an Ir-192 source
(Flexisource, Elekta Brachytherapy, Veenendaal, The Netherlands) in a specially de-
signed calibration phantom at a distance of 10 ± 0.1 mm [130]. Five irradiations
were perfomed for each MOSkin device. For each MOSkin a calibration factor N was
determined as N = Dcal/Vmean, where Dcal is the dose delivered to the MOSkin as
determined by the treatment planning system on the day of calibration, and Vmean is
the average MOSkin threshold shift across the 5 irradiations.
9.2.3 In-vivo Measurements and the Dual Purpose Probe
Immediately prior to commencing the TRUS based HDR pBT treatment four sterilised
MOSkin dosimeters were placed onto the TRUS probe (Type 8848, BK Medical Sys-
tems, Herlev, Denmark) and secured with Kapton tape. The dosimeters were placed
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with 1.5 cm spacing, with the most superiorly placed MOSkin 1 cm inferior to the
plane of the transverse transducer (Figure 9.3). So that the MOSkin dosimeters did
not perturb the transverse or sagittal images produced by the TRUS probe, they were
placed at an angle of 90°from the transducers on the surface of the probe. As per the
standard treatment protocol the TRUS probe was covered by an endorectal balloon to
aid in acquisition of high quality TRUS images. To provide an additional safeguard
against the risk of infection or breakage of the balloon, a condom was then placed over
the balloon before the procedure was commenced.
Figure 9.3: Placement of the MOSkin dosimeters on the TRUS probe, under the
endorectal balloon to produce the DPP.
Directly after treatment planning, and preceding delivery of the treatment, the
DPP was rotated by 90°such that the MOSkin dosimeters were oriented towards the
anterior rectal wall of the patient. The DPP was then stepped superiorly through the
patient so that the transverse transducer was located 1 cm superior to the base plane
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of the prostate. The position of the MOSkin dosimeters could now be located within
the reference frame of the BTPS to within 1 mm (k=2).
During treatment delivery the MOSkin dosimeters response was recorded using
the OneTouch readout system [131], allowing for wireless readout of the MOSkin
dosimeters via Bluetooth to a computer running the dedicated MOSkin OneTouch
software in the treatment console. An additional advantage of the OneTouch system
is online compensation for temperature dependence of the MOSkin dosimeters during
irradiation [131].
9.2.4 Measurement & Uncertainty Analysis
Upon completion of treatment rectal IVD measurements using the MOSkin dosimeters
were compared to doses predicted at the known points of interest (POIs) in the BTPS
(Figure 9.4). The MOSkin measured (DPP) and BTPS predicted (DBTPS) doses were
first compared via relative differences, i.e. ∆DPPvsBTPS = (DPP-DBTPS) / DPP.
As per the second aim of this study, the MOSkin measured vs BTPS predicted
doses were also analysed on a per catheter basis. Due to the continuous readout of the
OneTouch system, the dose deposited to each MOSkin on the DPP by each catheter
in the treatment plan could be determined in a straightforward manner due to the
gap in time between transit of the source through each catheter. Analysis of a dose
per dwell position was not attempted due to the low dose deposited at the position
of the MOSkin detectors on the TRUS probe from dwell positions in the anterior
portion of the prostate. The predicted dose to each of the MOSkins on the DPP
was determined using the Radcalc independent verification software (v6.4, Lifeline,
Melbourne, Florida) after DICOM transfer of the RTPlan file of the BTPS, due to the
Oncentra Prostate BTPS not providing the dose to each POI on a per catheter basis.
The total combined uncertainty of the MOSkin measurements was estimated to be
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11.5% (Table 9.1). The contribution towards the combined uncertainty from calibra-
tion of the dosimeters was approximately 1.8%, with 1.5% contribution from uncer-
tainty in the source air kerma strength (SK) and a further 1.0% from the phantom
assembly (source to detector distance), and dose calculation algorithm uncertainty
[56].
The change in response of the MOSkin dosimeters linearity during measurement
contributes an uncertainty of 1% [132], and the combined uncertainty of the repro-
ducibility and the precision of the system was approximately 1.5% [131]. Dependence
of the MOSkin readout on temperature was removed through the use of automatic
temperature compensation as discussed by Peters et al.[131]. The effect of energy
(distance) dependence of the MOSkins resulted in an uncertainty of 3.5% [133], and
angular dependence resulted in an uncertainty of 2% and 3% in the transverse and
longitudinal directions, respectively [132].
Table 9.1: Uncertainty analysis for MOSkin measurements performed in this study.
Uncertainty(%) (k=1)
Contribution to uncertainty from MOSkin calibration
Source air kerma strength definition ±1.5
Phantom assembly, dose calculation algorithm ±1.0
Contribution to uncertainty from patient measurements
Linearity ±1.0
Reproducibility and precision ±1.5
Energy dependence ±3.5
Angular dependence (transverse) ±2.0
Angular dependence (longitudinal) ±3.0
Localisation of measurement point within BTPS coor-
dinate system
±9.8
Total combined measurement uncertainty ±11.5
The dominant contributor towards the total combined uncertainty of the MOSkin
measurements was the uncertainty in localizing the MOSkin dosimeters in the BTPS
coordinate system. Due to the steep dose gradients in the area of the anterior rectal
wall, small geometric errors in placement of the MOSkin dosimeter may result in sub-
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stantial dose errors. Therefore, this uncertainty was quantified by creating a region
of interest (ROI) with radius of 1 mm (approximately equal to the accuracy of place-
ment of the MOSkin on the DPP), centered on each POI within the BTPS, as shown
in Figure 9.4. The maximum and minimum dose to these ROIs was then determined
in the BTPS, the difference between these maximum and minimum doses was then ex-
pressed as a percentage of the expected MOSkin dose at the POI and averaged across
all measurement points in the study. This resulted in an expected 9.8% contribution
towards MOSkin measurement uncertainty as shown in Table 9.1.
Figure 9.4: Creation of ROI’s around MOSkin measurement points (red shperes),
shown on sagittal view of an example plan with prostate contour (red), urethra (yel-
low), and dwell position within an example catheter (red dot in yellow cylinder).
9.3 Results
Of the 80 dosimeter measurements across the 20 measured fractions, 17 measure-
ments (21%) were excluded from the analysis due to dosimeter malfunction (loss of
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signal). The rate of occurrence of dosimeter malfunction decreased across the length
of the study due to an improved method of securing the MOSkins to the TRUS probe,
whereby a layer of Kapton tape was placed over the dosimeters before covering with the
endorectal balloon. The average number of MOSkin measurement points per fraction
was 3.
Sixty-three measurements were therefore included for analysis in this study. The
average dose measured by the MOSkins was 414 cGy ± 93 cGy (k=1). The range
of measured MOSkin doses was from 219 cGy to 575 cGy. The average ∆DPPvsBTPS
was -1.6% ± 11.1% (k=1), with a maximum of 25.7% and a minimum of -29.2%.
Fourty-three measurements (68%) had a ∆DPPvsBTPS less than ±11.5% (the total
combined uncertainty estimate) relative to the BTPS predicted dose. No fractions
included in this study had greater than 50% of the MOSkin measurements with
∆DPPvsBTPS outside of the ±11.5% combined measurement uncertainty. A histogram
of the ∆DPPvsBTPS across the 20 measured fractions is shown in Figure 9.5.
9.3. Results 124
Figure 9.5: Histogram of ∆DPPvsBTPS values for 63 MOSkin measurement points
across 20 treatment fractions.
The average number of catheters in the 20 MOSkin measured fractions was 17
(range 15-20), and the total number of catheters measured across the 20 fractions was
342. When analysing on a per catheter basis the total number of MOSkin measured
points was 1071. The average MOSkin measured dose per catheter was 24.4 cGy ±
23.6 cGy (k=1) with a range of 0.7 cGy to 138.3 cGy.
The results of the per catheter analysis of ∆DPPvsBTPS are summarized in Ta-
ble 9.2 along with the differences between MOSkin measured and BTPS predicted
doses in absolute terms. The average ∆DPPvsBTPS per catheter was 2.5% ± 16.9%
(k=1). Sixty-four percent of the per catheter MOSkin measurements (n=685) had a
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∆DPPvsBTPS less than ±11.5% (the total combined uncertainty estimate) relative to
the BTPS predicted dose. A histogram of the ∆DPPvsBTPS across the 342 measured
catheters is shown in Figure 9.6.
Table 9.2: Uncertainty analysis for MOSkin measurements performed in this study.
∆DPPvsBTPS (%) Dose Difference (cGy)
Average 2.5 0.1
Standard Deviation 16.9 5.7
Minimum -57.9 -35.8
Maximum 71.4 24.7
Of the 1071 available data points for the per catheter analysis, 25% of the MOSkin
measurements had a BTPS predicted dose per catheter less than 10 cGy. Removal
of these points from the ∆DPPvsBTPS analysis due to their clinical insignificance (low
contribution to total rectal dose) resulted in an improved average per catheter of
∆DPPvsBTPS = 1.0% and an average absolute dose difference of 0.0 cGy.
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Figure 9.6: Histogram of ∆DPPvsBTPS values for 1071 MOSkin measurement points
across 342 measured catheters.
9.4 Discussion
The average ∆DPPvsBTPS per fraction found in the 20 fractions included this study
was -1.6% ± 11.1% (k=1). This result compares favourably with the previous results
presented by Carrara et al. [57] where DPP measurements over 18 TRUS based
HDR pBT fractions yielded an agreement with treatment planning predicted doses
to within -2.1% ± 8.3% (k=1). Carrara et al. performed a subsequent comparison
of the DPP measurements with a treatment plan reconstructed on post-treatment
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images and found an improved agreement of -0.6% ± 4.1% (k=1). This difference was
attributed to a systematic shift of the plastic catheters towards the rectum in the time
between imaging and treatment [57]. The excellent agreement between the results
of this study and those described by Carrara et al. reinforce the applicability of the
MOSkin dosimeters (and their use as part of a DPP) for in-vivo rectal dosimetry during
TRUS based HDR pBT irrespective of the nuances involved in individual departments
clinical workflows.
The average ∆DPPvsBTPS per catheter found in this study was 2.5%± 16.9% (k=1).
When catheters with small contributions (<10 cGy) to the MOSkin measurement
were excluded from the analysis, the average ∆DPPvsBTPS per catheter improved to
1.0% ± 15.7% (k=1). Modern HDR pBT treatment regimens often deliver the full
brachytherapy prescription dose in a single fraction [134, 135], and it is therefore
necessary for devices performing IVD to report dose to OARs prior to the end of the
treatment fraction. The results presented in this study show that this may indeed
by feasible using MOSkin dosimeters as part of a DPP. Even after excluding MOSkin
measurements from analysis due to the small (<10 cGy), contribution to the total
rectal dose, a minimum of 2 MOSkin dosimeters were available for analysis across all
catheters measured in this study.
However, analysis of the per catheter results in the context of treatment verification
is difficult. This is exemplified in Figure 9.7, where catheter 5 in the treatment plan has
a ∆DPPvsBTPS of -19.1%, but the total treatment fraction ∆DPPvsBTPS is only +0.2%.
This raises the question of whether or not it would be appropriate to interrupt the
treatment after catheter 5 to investigate a potential error, and whether or not the
per catheter differences between MOSkin measured and BTPS predicted doses are
indicative of those accumulated across a total treatment fraction. The answer to this
question likely depends on the aim of the measurement.
9.4. Discussion 128
Figure 9.7: BTPS predicted (blue) vs MOSkin measured (red) dose accumulated across
catheters for one of the fractions included in this study.
If the aim of the measurement is to verify the dose delivered to the rectum it may
not be feasible to rely on the per catheter results to predict the total dose to the
rectum from the entire treatment fraction (as shown in Figure 9.7). This finding is
further highlighted through additional analysis of the per catheter data. For example,
for MOSkin measurement points that had a total treatment fraction ∆DPPvsBTPS of
less than 11.5% (n = 43), all but 5 measurements consisted of at least 1 catheter with a
∆DPPvsBTPS of greater than 11.5%. Nevertheless, even though it was not exemplified
in this study, a consistent ∆DPPvsBTPS of greater than 11.5% for multiple catheters
in sequence may indicate a potential overdose to the rectum for the entire treatment
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fraction and could be cause to interrupt the treatment to investigate the source of the
error.
If the aim of the measurement however is to verify correct delivery of the TRUS
based HDR pBT treatment, the per catheter results may be of more relevance. For
the example case shown in Figure 9.7, even though the total dose to the rectum for the
entire fraction is within tolerance, the -19.1% error for catheter 5 may indicate a po-
tential error in the delivery of this catheter. If the error for this catheter was related to
an incorrect catheter reconstruction in the BTPS, it may have resulted in an overdose
to the urethra or significant loss in target coverage. Analysis of the 2 other MOSkin
measurement points available for this catheter showed a ∆DPPvsBTPS of -6.5%, and
-1.2%. Therefore, it is unlikely that there was a treatment delivery error related to
this catheter in this example. Anderson et al. were able to overcome the issue of low
signal at the position of the detector by placing an optically stimulated luminescence
detector within a brachytherapy needle during an gynaecological brachytherapy treat-
ment [136]. When the detector is placed within a brachytherapy needle, it is closer to
the Ir-192 source and thus collects a sufficient signal to determine the dose per dwell
position for every needle. It should be noted however that gynaecological brachyther-
apy treatments often consist of less needles than prostate brachytherapy treatments
and often have larger dwell times, which would allow the detector to collect a larger
signal per dwell position.
Despite 25% of MOSkin measurements being excluded from the per catheter anal-
ysis due to low signal, there was still a minimum 2 MOSkin dosimeters available per
catheter during each fraction being considered. Inclusion of multiple dosimeters in the
per catheter analysis results in an improved redundancy to potential dosimeter errors
and an increased ability to detect potential treatment delivery errors. For example,
it may be appropriate to investigate a potential treatment delivery error if more than
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50% of MOSkin dosimeters are showng a ∆DPPvsBTPS of greater than 11.5% on a
per catheter basis. No catheters analysed in this study were found to have >50% of
measurement points with a ∆DPPvsBTPS >11.5%.
One limitation of this study is that the total combined uncertainty of the mea-
surement (11.5%, k=1) may be so large that treatment delivery errors or incorrectly
predicted doses to the rectum may go undetected. From Table 9.1, it can be seen the
dominant contributor towards this measurement uncertainty is the localisation of the
MOSkin measurement point within the coordinate system of the BTPS. Improvement
of this localisation to within 0.5 mm would reduce the total combined uncertainty to
approximately 7% and will result in an improve sensitivity and specificity of the DPP.
This could be achieved through fabrication of TRUS probes with well-defined recesses
for placement of MOSkin dosimeters into the housing of the probe. Future studies are
planned to validate further the MOSkin sensitivity-specificity by performing phantom
measurements.
Another limitation of this study in the context of treatment delivery verification is
that the measured MOSkin dose from anterior catheters in the plan is quite small. For
example, the average MOSkin measured dose for catheters 1-10 (the most posterior
catheters in our workflow) in this study was 33.5 cGy, as compared to 13.0 cGy for
catheter numbers >10 (the most anterior catheters in our clinical workflow). This may
result in a decreased sensitivity and specificity when attempting to catch treatment
delivery errors for anterior catheters due to either: a) the catheters being excluded
from analysis (catheter dose at MOSkin level <10 cGy), or b) small deviations be-
tween planned and delivered dwell positions not resulting in a significant difference in
dose measured at the DPP. These small deviations may still result in a significantly
increased dose to the urethra or a loss of target coverage, as shown in Chapter 5.
Therefore, analysis of MOSkin measurements per catheter basis may not be sensitive
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enough to detect all types of potential errors in the HDR pBT treatment planning
and delivery process (such as those identified in Chapter 4 of this thesis). To quan-
tify the likelihood of this occurring, future studies are planned to examine the effect of
treatment delivery errors MOSkin measured doses through simulation of these delivery
errors in gel phantom measurements involving the DPP.
9.5 Conclusion
This chapter presents a method for in-vivo rectal dosimetry during TRUS based HDR
pBT using MOSkin dosimeters coupled to a TRUS probe. The results of the study
were found to agree well with previously published data, despite differences in clinical
workflows. Analysis of MOSkin measured doses as compared to BTPS predicted doses
on a per catheter basis was found to be feasible. The use of MOSkin dosimeters as
part of a DPP for in-vivo rectal dosimetry is suitable for detecting clinically relevant
errors in the TRUS based HDR pBT treatment planning and delivery process that
affect the dose delivered to the rectum. More studies are required however before real
time error thresholds can be confidently applied to catch potential errors in treatment
delivery prior to the end of treatment using this methodology. The results presented
in this chapter resulted in an increased confidence of the dose delivery accuracy of the
TRUS based HDT pBT at St George Hospital and contributed in the move towards a
delivery of the HDR pBT treatment as a single fraction dose.
Chapter 10
Conclusion
The aim of this thesis was to identify potential treatment planning and delivery errors
during TRUS based HDR pBT and investigate the feasibility of eliminating these
errors through the introduction of routine IVTV. This aim was achieved through
firstly performing a risk-based analysis to develop a QM program for TRUS based
HDR pBT. It was acknowledged through this risk based analysis that IVTV would
be able to identify a significant number of the identified failure modes in the TRUS
based HDR pBT treatment planning and delivery process. Subsequent chapters of this
thesis then showed that in-vivo source tracking using the MP is capable of capturing
clinically relevant source positioning errors and that real-time IVD using MOSkins is
achievable.
10.1 Final Summary
In Chapter 4 of this thesis FMEA was shown to be a valuable tool in developing a QM
program for TRUS based HDR pBT treatments. In performing this analysis, several
potential errors were identified that were not previously considered when following
traditional QA methods. It was also identified in this chapter that a large number
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of these errors were related to human and procedural faults. This finding emphasised
the importance of performing IVTV as an additional safeguard against planning and
delivery errors during TRUS based HDR pBT.
Clinically relevant in-vivo source tracking error thresholds were derived in Chapter
5 of this thesis through simulation of source positioning errors in the BTPS. Derivation
of in-vivo source tracking error thresholds showed that the error thresholds were depen-
dent on: the direction of the error, the patient geometry, and the endpoint. To prevent
delivering too high dose to OARs error thresholds in the anterior/posterior and me-
dial/lateral directions were found to be smaller than those in the cranial/caudal direc-
tion, and the urethra D1cc was found to be a more sensitive endpoint in deriving error
thresholds than the rectum D2cc. In terms of target coverage, smaller error thresholds
in the cranial/caudal direction were derived compared to the anterior/posterior and
medial/lateral directions.
In Chapter 6 of this thesis TG43 parameters for the Ir-192 Flexisource were calcu-
lated using the Geant4 MC simulation toolkit. Both the radial dose and 2D anisotropy
functions were calculated and compared to previously published benchmark data that
is used in the BTPS. Both the radial dose and 2D anisotropy functions calculated
in Chapter 6 were found to agree with the previously published benchmark data to
within an expanded uncertainty of 1.2%. The work presented in Chapter 6 was essen-
tial in validating the Ir-192 Flexisource MC model prior to performing investigations
in subsequent chapters.
The MC model of the Ir-192 Flexisource developed in Chapter 6 was used in Chap-
ter 7 when simulating the source inside the patient and examining the feasibility of
using the MP121 for in-vivo source tracking in heterogeneous media. It was deter-
mined that the MP121 could localise the Ir-192 source to within 2.1 ±2 0.8 mm (k=1)
inside a patient geometry, relative to the known source positions from the BTPS. If
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the entire patient geometry was assigned a uniform density of 1 g/cm2 and a material
of water, this source tracking accuracy improved to less than 1 mm. Therefore, unless
prior knowledge of the 3D patient geometry, including size and position of hetero-
geneities exists, 2 mm may be the upper bound of source tracking accuracy using the
MP121 placed beneath the patient inside the carbon fibre couch.
In Chapter 8, the work presented in Chapter 7 was extended so that the patient
geometry now also included a TRUS probe within the rectum, as would be the case
when performing in-vivo source tracking during TRUS based HDR pBT. In the pres-
ence of the TRUS probe, the average 3D error for source tracking using the MP900
across three complete patient treatments (in three different patient geometries) was
11.9 ±2 2.4 mm (k=1). Without the TRUS probe present, the MP900 source tracking
accuracy improved to 1.5 ±2 0.3 mm (k=1). A modification of the source tracking
algorithm was implemented which applied a threshold that ignored the detectors in
the MP900 array that were shadowed by the TRUS probe. Implementation of this
modified source tracking algorithm improved the MP900 source tracking accuracy in
the presence of the probe to 1.8 ±2 0.4 mm (k=1). Therefore, through implementation
of the modified source tracking algorithm, an equivalent source tracking accuracy in
the presence of the TRUS probe can be achieved to in-vivo source tracking accuracy
without a TRUS probe present.
Finally, in Chapter 9 MOSkin dosimeter in-vivo rectal dosimetry measurements
were performed as part of a clinical study across 20 treatment fractions. The MOSkin
dosimeters were coupled to the TRUS probe used for imaging and treatment planning
to form a dual purpose probe (DPP). The average relative difference between MOSkin
measured and BTPS predicted doses was -1.6% ± 11.1% (k=1), with a maximum of
25.7% and a minimum of -29.2%. When analysing on a per catheter basis, the average
relative percent difference per catheter was 2.5% ± 16.9% (k=1). Per catheter analysis
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of the MOSkin measurements was found not to predict the total treatment fraction
dose to the rectum for all patients in the study. Additionally, it was determined that
analysis on a per catheter basis may not be sensitive enough to detect all types of
potential errors in the HDR pBT treatment planning and delivery process.
10.2 Future Work
Risk-based analysis of the TRUS based HDR pBT planning and treatment process
identified a number of potential errors. These errors were simulated in the BTPS, so
as to derive clinically significant error thresholds for in-vivo source tracking and MC
simulations used to determine the feasibility of using the MP to capture source posi-
tioning errors of this magnitude. Finally, IVD using MOSkin detectors was performed
during 19 patient treatment fractions to validate the dose to the rectum during these
treatments and to examine the feasibility of performing real time analysis of this met-
ric. Despite the successfulness of these investigations, there are a number of studies
that may still be performed to further improve these two IVTV techniques.
Firstly, the in-vivo source positioning error thresholds derived in Chapter 5 are
specific to the catheter implant patterns, and plan optimisation techniques used at
STGCCC. In this chapter it was also observed that there was significant variation in
the proposed source tracking error threshold from patient to patient. This is likely
due to the differences in proximity of the catheters to OARs such as the rectum and
urethra. Subsequently, it is hypothesised that appropriate in-vivo source tracking er-
ror thresholds are also likely to depend on the catheter implant pattern rules and
plan optimisation techniques used at different departments. Future studies will exam-
ine this by requesting individual departments to create a treatment plan on a single
TRUS dataset. Source positioning errors will then be simulated on these plans as was
performed in Chapter 5, and the spread in appropriate in-vivo source tracking error
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thresholds across departments will be examined.
Secondly, as mentioned in Chapter 7 and Chapter 8, the accuracy of in-vivo source
tracking using the MP as determined through MC simulations in these chapters likely
presents the upper bound of their limit. This is because the MC simulations assume
a perfect registration between the MP and the BTPS coordinate systems. In reality,
this will not be the case, and any uncertainty in registration between these coordinate
systems will carry through as a systematic error in source tracking accuracy using the
MP. Additionally, the ability of the MP121 and MP900 to detect dwell position errors
will also be affected by any dependence of the signal collected by the device on the
distance between the source and the detector array (e.g. due to the low signal col-
lected at extended distances, any dose rate dependence, and any energy dependence).
Therefore the 2 mm source tracking accuracy calculated in Chapter 7 and Chapter 8
will likely not be achievable in a clinical environment.
To overcome these challenges, and to validate the MC results experimentally, future
studies will investigate combining the MP with an EMT system to localise the MP
position in world coordinates, relative to the TRUS probe (which controls the origin of
the BTPS coordinate system relative to the MP). These experiments will be performed
in gel phantoms so that end-to-end validation of the TRUS based HDR pBT technique
can be performed, and the upper bound of source tracking accuracy using the MP
can be determined experimentally. To address any dose rate and energy dependence
identified, the detector array may be calibrated at the source to detector distances
expected during in-vivo source tracking (e.g. 15-20 cm). Furthermore, errors identified
in Chapter 4 of this thesis can be simulated to determine the sensitivity and specificity
of the MP in catching these errors.
Finally, the study outlined in Chapter 9 shows that it is feasible to use MOSkin
dosimeters coupled to a TRUS probe to confirm the dose delivered to the rectum
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during TRUS based HDR pBT. It is not clear however whether the methodology is
sensitive enough to detect potential high risk errors in the TRUS based HDR pBT
treatment planning and delivery identified in Chapter 4 of this thesis. Future studies
are planned, also utilising gel phantoms, where these errors will be simulated and
MOSkin measurements performed as part of a DPP to determine the sensitivity and
specificity of the IVD technique. Comparisons with in-vivo source tracking using
the MP can then be performed. Furthermore, the ability of the MOSkin dosimeters
to perform both IVD and in-vivo source tracking will be investigated, as shown by
Linares-Rosales, et al.[137]
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